

Matsatoshi Kudo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4360034/publications.pdf>

Version: 2024-02-01

1,162
papers

76,494
citations

906

116
h-index

983

237
g-index

1182
all docs

1182
docs citations

1182
times ranked

33991
citing authors

#	ARTICLE	IF	CITATIONS
1	Does first-line treatment have prognostic impact for unresectable <scp>HCC</scp>?â€”Atezolizumab plus bevacizumab versus lenvatinib. Cancer Medicine, 2023, 12, 325-334.	2.8	25
2	A novel method of papilla fixation for difficult biliary cannulation without using a pancreatic duct guidewire: non-guidewire fixation method. Endoscopy, 2022, 54, 101-102.	1.8	1
3	Across-the-papilla side-by-side placement of 6-mm fully covered metallic stents for malignant hilar biliary obstruction: a novel concept that may facilitate reintervention. Endoscopy, 2022, 54, E102-E105.	1.8	4
4	Tissue harmonic versus contrast-enhanced harmonic endoscopic ultrasonography for the diagnosis of pancreatic tumors: Prospective multicenter study. Digestive Endoscopy, 2022, 34, 198-206.	2.3	10
5	Report of the 22nd nationwide follow-up Survey of Primary Liver Cancer in Japan (2012â€“2013). Hepatology Research, 2022, 52, 5-66.	3.4	46
6	Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience. Cancer Reports, 2022, 5, e1464.	1.4	43
7	Utility of contrast-enhanced harmonic endoscopic ultrasonography for T-staging of patients with extrahepatic bile duct cancer. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 3254-3260.	2.4	4
8	Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity. Journal of Histochemistry and Cytochemistry, 2022, 70, 53-81.	2.5	6
9	How should radiation exposure be handled in fluoroscopy-guided endoscopic procedures in the field of gastroenterology?. Digestive Endoscopy, 2022, 34, 890-900.	2.3	9
10	Quantitative Evaluation of Fatty Metamorphosis and Fibrosis of Liver Based on Models of Ultrasound and Light Propagation and Its Application to Hepatic Disease Diagnosis. , 2022, , 215-223.		0
11	Clinical Significance of the Duality of Wnt/ β 2-Catenin Signaling in Human Hepatocellular Carcinoma. Cancers, 2022, 14, 444.	3.7	20
12	Value of artificial intelligence with novel tumor tracking technology in the diagnosis of gastric submucosal tumors by contrast-enhanced harmonic endoscopic ultrasonography. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 841-846.	2.8	10
13	Response Evaluation Criteria in Cancer of the liver version 6 (Response Evaluation Criteria in Cancer) Tj ETQq1 1 0.784314 rgBT /Over	3.4	12
14	Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology, The, 2022, 23, 77-90.	10.7	526
15	LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC). Journal of Clinical Oncology, 2022, 40, TPS494-TPS494.	1.6	2
16	Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.. Journal of Clinical Oncology, 2022, 40, 379-379.	1.6	235
17	Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma. Liver Cancer, 2022, 11, 354-367.	7.7	44
18	Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment. CardioVascular and Interventional Radiology, 2022, 45, 405-412.	2.0	35

#	ARTICLE	IF	CITATIONS
19	Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 76, 862-873.	3.7	568
20	Artificial intelligence (AI) models for the ultrasonographic diagnosis of liver tumors and comparison of diagnostic accuracies between AI and human experts. <i>Journal of Gastroenterology</i> , 2022, 57, 309-321.	5.1	19
21	Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma. <i>Liver Cancer</i> , 2022, 11, 290-314.	7.7	30
22	Endoscopic Reintervention for Recurrence of Malignant Biliary Obstruction: Developing the Best Strategy. <i>Gut and Liver</i> , 2022, 16, 525-534.	2.9	6
23	Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2022, 11, 87-93.	7.7	20
24	Comparison of Radiation Exposure between Endoscopic Ultrasound-Guided Hepaticogastrostomy and Hepaticogastrostomy with Antegrade Stenting. <i>Journal of Clinical Medicine</i> , 2022, 11, 1705.	2.4	0
25	Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. <i>Hepatology</i> , 2022, 76, 1000-1012.	7.3	114
26	Reply to Response to "A Case of Ulcerative Colitis Relapse Characterized by Systemic Type I Interferon Responses After COVID-19 Vaccination" by Mungmunpuntipantip and Wiwanitkiton. <i>Inflammatory Bowel Diseases</i> , 2022, .	1.9	0
27	Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. <i>European Journal of Cancer</i> , 2022, 167, 1-12.	2.8	43
28	Comparison between gradient and spin-echo (GRASE) and compressed sensing sequences for single breath-hold three-dimensional magnetic resonance cholangiopancreatography in patients with T1 hyperintense bile. <i>European Journal of Radiology</i> , 2022, 150, 110279.	2.6	0
29	The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 186.	3.7	44
30	Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies. <i>Clinical Cancer Research</i> , 2022, 28, 3443-3451.	7.0	19
31	Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC stage patients classified as beyond up to seven criteria " Multicenter analysis. <i>Hepatology Research</i> , 2022, 52, 308-316.	3.4	25
32	Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF Trial). <i>Liver Cancer</i> , 2022, 11, 209-218.	7.7	65
33	Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2022, 11, 1-8.	7.7	22
34	What is CEUS LI-RADS?. <i>Choonpa Igaku</i> , 2022, 49, .	0.0	0
35	Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2547-2554.	7.0	32
36	Role of phlebotomy in the treatment of liver damage related to erythropoietic porphyria. <i>Scientific Reports</i> , 2022, 12, 6100.	3.3	4

#	ARTICLE	IF	CITATIONS
37	Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials. <i>Clinical Cancer Research</i> , 2022, 28, 2297-2305.	7.0	8
38	Efficacy of EUS-guided celiac plexus neurolysis in combination with EUS-guided celiac ganglia neurolysis for pancreatic cancer-associated pain: a multicenter prospective trial. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1196-1201.	2.2	7
39	A Mouse Model of Acute and Chronic Pancreatitis. <i>Current Protocols</i> , 2022, 2, e422.	2.9	4
40	New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1110-1119.	2.2	19
41	Clinical Practice Guidelines for Hepatic Arterial Infusion Chemotherapy with a Port System Proposed by the Japanese Society of Interventional Radiology and Japanese Society of Implantable Port Assisted Treatment. <i>Liver Cancer</i> , 2022, 11, 407-425.	7.7	9
42	Performance evaluation of the Elecsys α -fetoprotein (AFP) and Elecsys AFP assays for hepatocellular carcinoma diagnosis. <i>JGH Open</i> , 2022, 6, 292-300.	1.6	10
43	Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. <i>Hepatology Communications</i> , 2022, 6, 1776-1785.	4.3	7
44	How Compatible Are Immune Checkpoint Inhibitors and Thermal Ablation for Liver Metastases?. <i>Cancers</i> , 2022, 14, 2206.	3.7	3
45	C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. <i>Scientific Reports</i> , 2022, 12, 8421.	3.3	4
46	Case Report: New-Onset Rheumatoid Arthritis Following COVID-19 Vaccination. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	17
47	Clinical implication of immune checkpoint inhibitor on the chronic hepatitis B virus infection. <i>Hepatology Research</i> , 2022, 52, 754-761.	3.4	7
48	A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	8.6	17
49	Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. , 2022, 1, .		298
50	Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. , 2022, 10, e004205.		26
51	Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?. <i>Liver Cancer</i> , 2022, 11, 283-289.	7.7	4
52	Utility of contrast-enhanced harmonic EUS for diagnosis of portal vein invasion by pancreatic cancer. <i>Endoscopic Ultrasound</i> , 2022, 11, 401.	1.5	5
53	Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 857-864.	1.6	3
54	Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial. <i>Liver Cancer</i> , 2022, 11, 558-571.	7.7	6

#	ARTICLE	IF	CITATIONS
55	Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study. Liver Cancer, 2022, 11, 527-539.	7.7	16
56	Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL). Journal of Gastroenterology, 2022, 57, 587-597.	5.1	5
57	Utility of contrast-enhanced harmonic endoscopic ultrasonography for predicting the prognosis of pancreatic neuroendocrine neoplasms. Digestive Endoscopy, 2021, 33, 829-839.	2.3	21
58	Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1812-1819.	2.8	28
59	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology, 2021, 73, 158-191.	7.3	235
60	Serum Levels of α -Fetoprotein Increased More Than 10 Years Before Detection of Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2021, 19, 162-170.e4.	4.4	24
61	Improved detection of liver metastasis using Kupffer-phase imaging in contrast-enhanced harmonic EUS in patients with pancreatic cancer (with video). Gastrointestinal Endoscopy, 2021, 93, 433-441.	1.0	22
62	Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. Liver International, 2021, 41, 598-607.	3.9	13
63	Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240. Cancer, 2021, 127, 865-874.	4.1	20
64	Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. JHEP Reports, 2021, 3, 100215.	4.9	31
65	Analysis of Patient Outcome after Non-curative Resection for Hepatocellular Carcinoma Using Nationwide Survey Data in Japan. World Journal of Surgery, 2021, 45, 607-614.	1.6	5
66	Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma. Gastroenterology Report, 2021, 9, 133-138.	1.3	21
67	A case with eosinophilic gastroenteritis exhibiting enhanced TNF- α and IL-6 responses. Clinical Journal of Gastroenterology, 2021, 14, 511-516.	0.8	2
68	Ultrasound fusion imaging technologies for guidance in ablation therapy for liver cancer. Choonpa Igaku, 2021, 48, 359-365.	0.0	0
69	Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy. Liver Cancer, 2021, 10, 85-93.	7.7	22
70	Utility of a 20G needle with a core trap in EUS-guided fine-needle biopsy for gastric submucosal tumors: A multicentric prospective trial. Endoscopic Ultrasound, 2021, 10, 134.	1.5	14
71	Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study. Journal of Gastroenterology, 2021, 56, 181-190.	5.1	20
72	Surveillance, Diagnosis, and Treatment Outcomes of Hepatocellular Carcinoma in Japan: 2021 Update. Liver Cancer, 2021, 10, 167-180.	7.7	17

#	ARTICLE	IF	CITATIONS
73	Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110109.	3.2	15
74	Impact of Multi-Drug Sequential Therapy on Survival in Patients with Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 1-9.	7.7	13
75	Impaired Response to Immunotherapy in Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma?. <i>Liver Cancer</i> , 2021, 10, 289-295.	7.7	6
76	IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 267-267.	1.6	226
77	A case with Crohn's disease-associated spondyloarthritis exhibiting enhanced pro-inflammatory cytokine responses to Toll-like receptor ligands. <i>Asian Pacific Journal of Allergy and Immunology</i> , 2021, , .	0.4	0
78	ALBI score and outcomes in patients with hepatocellular carcinoma: <i>post hoc</i> analysis of the randomized controlled trial KEYNOTE-240. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110399.	3.2	7
79	Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040.. <i>Journal of Clinical Oncology</i> , 2021, 39, 269-269.	1.6	37
80	What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?. <i>Liver Cancer</i> , 2021, 10, 115-125.	7.7	12
81	The AFSUMB consensus statements and recommendations for the clinical practice of contrast-enhanced ultrasound using sonazoid. <i>Journal of Medical Ultrasound</i> , 2021, 28, 59-82.	0.4	13
82	Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging. <i>European Radiology</i> , 2021, 31, 5615-5628.	4.5	14
83	Endoscopic papillotomy and papilloplasty: Effects on sphincter of Oddi functionality and outcomes. <i>Digestive Endoscopy</i> , 2021, 33, 924-926.	2.3	2
84	Current status of endoscopic resection intervention for hilar malignant biliary obstruction. <i>Digestive Endoscopy</i> , 2021, 33, 746-748.	2.3	6
85	Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. <i>British Journal of Cancer</i> , 2021, 124, 1388-1397.	6.4	39
86	Three-Dimensional Radiological Assessment of Ablative Margins in Hepatocellular Carcinoma: Pilot Study of Overlay Fused CT/MRI Imaging with Automatic Registration. <i>Cancers</i> , 2021, 13, 1460.	3.7	5
87	Image Guidance in Ablation for Hepatocellular Carcinoma: Contrast-Enhanced Ultrasound and Fusion Imaging. <i>Frontiers in Oncology</i> , 2021, 11, 593636.	2.8	14
88	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	27.8	649
89	A case with hepatic immune-related adverse events caused by nivolumab exhibiting impaired accumulation of regulatory T cells. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 1191-1196.	0.8	7
90	Intestinal Dysbiosis and Autoimmune Pancreatitis. <i>Frontiers in Immunology</i> , 2021, 12, 621532.	4.8	10

#	ARTICLE	IF	CITATIONS
91	Report of the 21st Nationwide Follow-up Survey of Primary Liver Cancer in Japan (2010–2011). Hepatology Research, 2021, 51, 355-405.	3.4	54
92	Should Contrast-Enhanced Harmonic Endoscopic Ultrasound Be Incorporated into the International Consensus Guidelines to Determine the Appropriate Treatment of Intraductal Papillary Mucinous Neoplasm?. Journal of Clinical Medicine, 2021, 10, 1818.	2.4	0
93	Effect of Diameter and Number of Hepatocellular Carcinomas on Survival After Resection, Transarterial Chemoembolization, and Ablation. American Journal of Gastroenterology, 2021, 116, 1698-1708.	0.4	17
94	Clinicopathological analysis of hepatic immune-related adverse events in comparison with autoimmune hepatitis and graft-versus host disease. Scientific Reports, 2021, 11, 9242.	3.3	9
95	Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?. Hepatobiliary Surgery and Nutrition, 2021, 10, 180-192.	1.5	47
96	Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial. Liver Cancer, 2021, 10, 249-259.	7.7	49
97	Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial. Liver Cancer, 2021, 10, 275-284.	7.7	29
98	Combination immunotherapy with anti-VEGF/TKI for hepatocellular carcinoma: present and future perspective. Hepatobiliary Surgery and Nutrition, 2021, 10, 241-245.	1.5	11
99	Case Report: A Case of Intestinal Behçet's Disease Exhibiting Enhanced Expression of IL-6 and Forkhead Box P3 mRNA After Treatment With Infliximab. Frontiers in Medicine, 2021, 8, 679237.	2.6	3
100	Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT. Journal of Gastroenterology, 2021, 56, 570-580.	5.1	6
101	Ramucirumab in patients with advanced hepatocellular carcinoma and elevated α -fetoprotein: Outcomes by treatment-emergent ascites. Hepatology Research, 2021, 51, 715-721.	3.4	5
102	Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Trial. Value in Health Regional Issues, 2021, 24, 82-89.	1.2	6
103	Comparison of efficacy and safety of entecavir and switching from entecavir to tenofovir alafenamide fumarate in chronic hepatitis B: Long-term effects from a prospective study. Hepatology Research, 2021, 51, 767-774.	3.4	7
104	Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression. Hepatology Research, 2021, 51, 880-889.	3.4	15
105	Successful use of two guidewires with different properties using a double-lumen catheter for postoperative biliary stricture. Endoscopy, 2021, , .	1.8	2
106	Biomarkers in autoimmune pancreatitis and immunoglobulin G4-related disease. World Journal of Gastroenterology, 2021, 27, 2257-2269.	3.3	9
107	Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer, 2021, 10, 181-223.	7.7	307
108	Artificial intelligence-based endoscopic diagnosis of colorectal polyps using residual networks. PLoS ONE, 2021, 16, e0253585.	2.5	8

#	ARTICLE	IF	CITATIONS
109	Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology. <i>Liver International</i> , 2021, 41, 2759-2767.	3.9	5
110	Efficacy of Over-The-Scope Clip Method as a Novel Hemostatic Therapy for Colonic Diverticular Bleeding. <i>Journal of Clinical Medicine</i> , 2021, 10, 2891.	2.4	6
111	Impact of hepatitis C virus on survival in patients undergoing resection of intrahepatic cholangiocarcinoma: Report of a Japanese nationwide survey. <i>Hepatology Research</i> , 2021, 51, 890-901.	3.4	5
112	The Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB) Guidelines for Contrast-Enhanced Endoscopic Ultrasound. <i>Ultrasound in Medicine and Biology</i> , 2021, 47, 1433-1447.	1.5	18
113	Usefulness of the Novel Snare-over-the-Guidewire Method for Transpapillary Plastic Stent Replacement (with Video). <i>Journal of Clinical Medicine</i> , 2021, 10, 2858.	2.4	2
114	Improved Tumor Response to Lenvatinib Re-Treatment after Failure of Immune Checkpoint Inhibitors in a Patient with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 535-538.	7.7	2
115	Case Report: Regulatory T Cell-Independent Induction of Remission in a Patient With Collagenous Colitis. <i>Frontiers in Medicine</i> , 2021, 8, 678268.	2.6	0
116	Plasmacytoid Dendritic Cells as a New Therapeutic Target for Autoimmune Pancreatitis and IgG4-Related Disease. <i>Frontiers in Immunology</i> , 2021, 12, 713779.	4.8	6
117	Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2021, 22, 991-1001.	10.7	179
118	Lack of response to immunotherapy in non-alcoholic steatohepatitis related hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 522-525.	1.5	9
119	Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 649-658.	8.1	58
120	Value of Low-Mechanical-Index Contrast-Enhanced Transabdominal Ultrasound for Diagnosis of Pancreatic Cancer: A Meta-analysis. <i>Ultrasound in Medicine and Biology</i> , 2021, 47, 3315-3322.	1.5	3
121	Diagnostic Value of EUS-Guided Fine-Needle Aspiration Biopsy for Gastric Linitis Plastica with Negative Endoscopic Biopsy. <i>Journal of Clinical Medicine</i> , 2021, 10, 3716.	2.4	7
122	Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 615-628.	7.7	31
123	Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study. <i>Scientific Reports</i> , 2021, 11, 16663.	3.3	30
124	Impact of COVID-19 on Hepatocellular Carcinoma Management: A Multicountry and Region Study. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1159-1167.	3.7	21
125	CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, 600-609.	3.7	127
126	NOD2 deficiency protects mice from the development of adoptive transfer colitis through the induction of regulatory T cells expressing forkhead box P3. <i>Biochemical and Biophysical Research Communications</i> , 2021, 568, 55-61.	2.1	4

#	ARTICLE	IF	CITATIONS
127	Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2991-3001.	1.6	257
128	Cumulative radiation doses from recurrent PET-CT examinations. <i>British Journal of Radiology</i> , 2021, 94, 20210388.	2.2	14
129	Can the Entire Ablative Hyperechoic Zone be Regarded as a Necrotic Lesion After Radiofrequency Ablation of the Liver?. <i>Ultrasound in Medicine and Biology</i> , 2021, 47, 2930-2935.	1.5	2
130	The radiation doses and radiation protection on the endoscopic retrograde cholangiopancreatography procedures. <i>British Journal of Radiology</i> , 2021, 94, 20210399.	2.2	9
131	Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 399-403.	7.7	21
132	Safety and Efficacy of amplitude-modulated radiofrequency electromagnetic fields in advanced hepatocellular carcinoma. <i>4open</i> , 2021, 4, 3.	0.4	2
133	Dual-Energy Computed Tomography of the Liver: Uses in Clinical Practices and Applications. <i>Diagnostics</i> , 2021, 11, 161.	2.6	16
134	Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody. <i>Liver Cancer</i> , 2021, 10, 380-393.	7.7	51
135	Clinical-Radiomic Analysis for Pretreatment Prediction of Objective Response to First Transarterial Chemoembolization in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 38-51.	7.7	58
136	Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 510-521.	7.7	23
137	Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). <i>Liver Cancer</i> , 2021, 10, 451-460.	7.7	5
138	IL-33 as a Critical Cytokine for Inflammation and Fibrosis in Inflammatory Bowel Diseases and Pancreatitis. <i>Frontiers in Physiology</i> , 2021, 12, 781012.	2.8	11
139	Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 583-592.	7.7	33
140	Analysis of Progression Time in Pancreatic Cancer including Carcinoma In Situ Based on Magnetic Resonance Cholangiopancreatography Findings. <i>Diagnostics</i> , 2021, 11, 1858.	2.6	4
141	A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion. <i>Liver Cancer</i> , 2021, 10, 539-544.	7.7	46
142	Intestinal Microbiota and Gene Expression Reveal Similarity and Dissimilarity Between Immune-Mediated Colitis and Ulcerative Colitis. <i>Frontiers in Oncology</i> , 2021, 11, 763468.	2.8	10
143	Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy. <i>Cancers</i> , 2021, 13, 5475.	3.7	10
144	Deep-learning framework based on a large ultrasound image database to realize computer-aided diagnosis for liver and breast tumors. , 2021, , .		3

#	ARTICLE	IF	CITATIONS
145	Accumulation of Genetic and Epigenetic Alterations in the Background Liver and Emergence of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease. <i>Cells</i> , 2021, 10, 3257.	4.1	6
146	Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study. <i>BMC Gastroenterology</i> , 2021, 21, 489.	2.0	0
147	Response Evaluation Criteria in Cancer of the Liver (RECICL 2021 revised version). <i>Acta Hepatologica Japonica</i> , 2021, 62, 823-829.	0.1	2
148	A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies. <i>Investigational New Drugs</i> , 2020, 38, 445-456.	2.6	16
149	Dual-frequency MR elastography to differentiate between inflammation and fibrosis of the liver: Comparison with histopathology. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 1053-1064.	3.4	6
150	Radiofrequency ablation for hepatocellular carcinoma: Clinical value of ultrasound-ultrasound overlay fusion for optimal ablation and local controllability. <i>Hepatology Research</i> , 2020, 50, 67-74.	3.4	14
151	REFLECT: a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. <i>Journal of Gastroenterology</i> , 2020, 55, 113-122.	5.1	123
152	Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. <i>Hepatology</i> , 2020, 72, 198-212.	7.3	92
153	Efficacy of a modified double-guidewire technique using an uneven double lumen cannula (uneven) Tj ETQq1 1 0.784314 rgBT /Overl... Endoscopy and Other Interventional Techniques, 2020, 34, 1432-1441.	2.4	18
154	Novel concept of bared type metallic stent for endoscopic bilateral stent-in-a-stent placement in patients with hilar malignant biliary obstruction (with video). <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2020, 27, 282-283.	2.6	12
155	Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib. <i>Liver Cancer</i> , 2020, 9, 73-83.	7.7	37
156	Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan. <i>Hepatology Research</i> , 2020, 50, 15-46.	3.4	111
157	Navigator-triggered and breath-hold 3D MRCP using compressed sensing: image quality and method selection factor assessment. <i>Abdominal Radiology</i> , 2020, 45, 3081-3091.	2.1	7
158	Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 93-104.	7.7	60
159	Response to the Letter to the Editor 'Reply to "Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrospective Study" by Dr. Peng Chen'. <i>Internal Medicine</i> , 2020, 59, 879-879.	0.7	0
160	Possible involvement of autophagy in esophageal ulcers in anorexia nervosa. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 473-476.	0.8	2
161	Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. <i>Gut</i> , 2020, 69, 1492-1501.	12.1	411
162	Liver Resection for Multiple Hepatocellular Carcinomas. <i>Annals of Surgery</i> , 2020, 272, 145-154.	4.2	61

#	ARTICLE	IF	CITATIONS
163	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 193-202.	1.6	1,255
164	The chances of hepatic resection curing hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 711-717.	3.7	41
165	Management of Hepatocellular Carcinoma in Japan: Current Trends. <i>Liver Cancer</i> , 2020, 9, 1-5.	7.7	18
166	Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 583-595.	7.7	71
167	Impacts of COVID-19 on Liver Cancers: During and after the Pandemic. <i>Liver Cancer</i> , 2020, 9, 491-502.	7.7	47
168	Severe Immune-Related Hepatitis Treated With Plasma Exchange. <i>Journal of Thoracic Oncology</i> , 2020, 15, e39-e42.	1.1	3
169	A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma. <i>Cancer Science</i> , 2020, 111, 3759-3769.	3.9	29
170	Endoscopic ultrasound-guided biliary drainage for malignant biliary obstruction with surgically altered anatomy: a multicenter prospective registration study. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482093096.	3.2	9
171	Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib. <i>JAMA Oncology</i> , 2020, 6, e204564.	7.1	746
172	Better Efficacy of Ramucirumab in Japanese Patients than in the Global Population with Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 232-244.	7.7	6
173	Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies. <i>Liver Cancer</i> , 2020, 9, 440-454.	7.7	10
174	A Paradigm Change in the Treatment Strategy for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 367-377.	7.7	22
175	A new era of systemic therapy for intermediate and advanced stage hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 530-533.	1.5	3
176	Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver – Update 2020 – WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. <i>Ultraschall in Der Medizin</i> , 2020, 41, 562-585.	1.5	130
177	Guidelines and Good Clinical Practice Recommendations for Contrast-Enhanced Ultrasound (CEUS) in the Liver – Update 2020 WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. <i>Ultrasound in Medicine and Biology</i> , 2020, 46, 2579-2604.	1.5	210
178	Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 2960-2970.	1.6	723
179	Histological diagnosis and grading of pancreatic neuroendocrine tumor by endoscopic ultrasound-guided fine needle biopsy using a 25-gauge needle with a core trap: A multicenter prospective trial. <i>Pancreatology</i> , 2020, 20, 1428-1433.	1.1	10
180	Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1/PD-L1 Checkpoint Blockade. <i>Cancers</i> , 2020, 12, 3048.	3.7	37

#	ARTICLE	IF	CITATIONS
181	Identification of serum IFN- γ and IL-33 as novel biomarkers for type 1 autoimmune pancreatitis and IgG4-related disease. <i>Scientific Reports</i> , 2020, 10, 14879.	3.3	32
182	Gd-EOB-DTPA-MRI Could Predict WNT/ β -Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 479-490.	7.7	42
183	Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials. <i>ESMO Open</i> , 2020, 5, e000797.	4.5	18
184	Sorafenib treatment by Child-Pugh score in Latin American patients with hepatocellular carcinoma. <i>Future Oncology</i> , 2020, 16, 2511-2520.	2.4	4
185	Artificial Intelligence in Medical Imaging and Its Application in Sonography for the Management of Liver Tumor. <i>Frontiers in Oncology</i> , 2020, 10, 594580.	2.8	21
186	Mucosal microbiota and gene expression are associated with long-term remission after discontinuation of adalimumab in ulcerative colitis. <i>Scientific Reports</i> , 2020, 10, 19186.	3.3	10
187	Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 629-639.	7.7	20
188	A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. <i>Liver Cancer</i> , 2020, 9, 245-260.	7.7	172
189	Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2020, 382, 1894-1905.	27.0	3,828
190	Ultrasound fusion imaging technologies for guidance in ablation therapy for liver cancer. <i>Journal of Medical Ultrasonics</i> (2001), 2020, 47, 257-263.	1.3	16
191	Partial Pancreatic Parenchymal Atrophy Is a New Specific Finding to Diagnose Small Pancreatic Cancer (≤ 10 mm) Including Carcinoma in Situ: Comparison with Localized Benign Main Pancreatic Duct Stenosis Patients. <i>Diagnostics</i> , 2020, 10, 445.	2.6	24
192	Treatment of hepatocellular carcinoma during the COVID-19 outbreak: The Working Group report of JAMT-HCC. <i>Hepatology Research</i> , 2020, 50, 1004-1014.	3.4	20
193	The Efficacy of Sonazoid-enhanced Ultrasonography in Decision-making for Liver Abscess Treatment. <i>Internal Medicine</i> , 2020, 59, 471-477.	0.7	6
194	Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma. <i>Oncology</i> , 2020, 98, 295-302.	1.9	24
195	Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial. <i>Journal of Gastroenterology</i> , 2020, 55, 627-639.	5.1	23
196	Requirement of Additional Surgery after Non-Curative Endoscopic Submucosal Dissection for Early Colorectal Cancer. <i>Journal of Investigative Surgery</i> , 2020, 34, 1-2.	1.3	0
197	Utility and Safety of a Novel Fully Covered Metal Stent in Unresectable Distal Malignant Biliary Obstruction. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3702-3709.	2.3	5
198	Effect of surgical margin width after R0 resection for intrahepatic cholangiocarcinoma: A nationwide survey of the Liver Cancer Study Group of Japan. <i>Surgery</i> , 2020, 167, 793-802.	1.9	36

#	ARTICLE	IF	CITATIONS
199	Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 307-319.	3.7	310
200	Deficiency of Gankyrin in the small intestine is associated with augmented colitis accompanied by altered bacterial composition of intestinal microbiota. <i>BMC Gastroenterology</i> , 2020, 20, 12.	2.0	3
201	Activation of interferon regulatory factor 7 in plasmacytoid dendritic cells promotes experimental autoimmune pancreatitis. <i>Journal of Gastroenterology</i> , 2020, 55, 565-576.	5.1	15
202	Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1. <i>Liver Cancer</i> , 2020, 9, 426-439.	7.7	26
203	Optimal cropping for input images used in a convolutional neural network for ultrasonic diagnosis of liver tumors. <i>Japanese Journal of Applied Physics</i> , 2020, 59, SKKE09.	1.5	6
204	Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1089.	3.7	119
205	IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. <i>Future Oncology</i> , 2020, 16, 975-989.	2.4	136
206	Endoscopic ultrasound-guided radiofrequency ablation of porcine liver. <i>Journal of Medical Ultrasonics</i> (2001), 2020, 47, 435-443.	1.3	1
207	Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. <i>Liver International</i> , 2020, 40, 2008-2020.	3.9	26
208	Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety-Assessment Cohort. <i>Oncologist</i> , 2020, 25, e1292-e1302.	3.7	33
209	A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy. <i>Liver Cancer</i> , 2020, 9, 119-137.	7.7	45
210	EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis. <i>Liver Cancer</i> , 2020, 9, 734-743.	7.7	35
211	Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update. <i>Liver Cancer</i> , 2020, 9, 640-662.	7.7	78
212	Effect of pembrolizumab (pembro) on hepatitis B viral (HBV) load and aminotransferase (ALT) levels in patients (pts) with advanced hepatocellular carcinoma (aHCC) in KEYNOTE-224 and KEYNOTE-240.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4587-4587.	1.6	2
213	Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 476-476.	1.6	28
214	RECIST v1.1 and irRECIST outcomes in advanced HCC treated with pembrolizumab (pembro).. <i>Journal of Clinical Oncology</i> , 2020, 38, 528-528.	1.6	1
215	The AFSUMB Consensus Statements and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound using Sonazoid. <i>Ultrasonography</i> , 2020, 39, 191-220.	2.3	58
216	Promising anticancer therapy: combination of immune checkpoint inhibitors and molecular-targeted agents. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 777-779.	1.5	5

#	ARTICLE	IF	CITATIONS
217	Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1274.	3.7	27
218	Clinical utility of treatment method conversion during single-session endoscopic ultrasound-guided biliary drainage. <i>World Journal of Gastroenterology</i> , 2020, 26, 947-959.	3.3	7
219	Endoscopic Ultrasound Fine-Needle Biopsy May Contribute to the Diagnosis of Malignant Lymph Nodes. <i>Clinical Endoscopy</i> , 2020, 53, 508-509.	1.5	1
220	Gankyrin Contributes to Tumorigenesis and Chemoresistance in Sporadic Colorectal Cancer. <i>Digestion</i> , 2019, 100, 192-200.	2.3	4
221	Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis. <i>Liver Cancer</i> , 2019, 8, 121-129.	7.7	159
222	Clinical efficacy and safety of endoscopic ultrasoundâ€‘guided gallbladder drainage replacement of percutaneous drainage: A multicenter retrospective study. <i>Digestive Endoscopy</i> , 2019, 31, 180-187.	2.3	31
223	Heterogeneity of Epigenetic and Epithelial Mesenchymal Transition Marks in Hepatocellular Carcinoma with Keratin 19 Proficiency. <i>Liver Cancer</i> , 2019, 8, 239-254.	7.7	14
224	A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation. <i>Journal of Gastroenterology</i> , 2019, 54, 171-181.	5.1	67
225	Biology and significance of alphaâ€‘fetoprotein in hepatocellular carcinoma. <i>Liver International</i> , 2019, 39, 2214-2229.	3.9	327
226	B-Mode Ultrasonography versus Contrast-Enhanced Ultrasonography for Surveillance of Hepatocellular Carcinoma: A Prospective Multicenter Randomized Controlled Trial. <i>Liver Cancer</i> , 2019, 8, 271-280.	7.7	48
227	Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials. <i>Liver Cancer</i> , 2019, 8, 221-238.	7.7	51
228	Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Childâ€‘Pugh A Liver Function: A Proof-Of-Concept Study. <i>Cancers</i> , 2019, 11, 1084.	3.7	200
229	Risk factors for local recurrence and appropriate surveillance interval after endoscopic resection. <i>World Journal of Gastroenterology</i> , 2019, 25, 1502-1512.	3.3	33
230	Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma. <i>Oncology</i> , 2019, 97, 277-285.	1.9	66
231	Tu1955 COMPUTER-AIDED DIAGNOSIS BASED ON CONVOLUTIONAL NEURAL NETWORK SYSTEM USING ARTIFICIAL INTELLIGENCE FOR COLORECTAL POLYP CLASSIFICATION. <i>Gastrointestinal Endoscopy</i> , 2019, 89, AB631.	1.0	1
232	Intestinal dysbiosis mediates experimental autoimmune pancreatitis via activation of plasmacytoid dendritic cells. <i>International Immunology</i> , 2019, 31, 795-809.	4.0	26
233	Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study. <i>Cancers</i> , 2019, 11, 952.	3.7	114
234	Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th) Tj ETQq0 0 0 ggBT /Overlock 10 Tf	3.4	399

#	ARTICLE	IF	CITATIONS
235	Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma. British Journal of Cancer, 2019, 121, 218-221.	6.4	22
236	Novel concept using a plastic stent for endoscopic ultrasound-guided hepaticogastrostomy adjusting the length according to the patient's anatomy. Endoscopy, 2019, 51, E362-E363.	1.8	4
237	Conversion of percutaneous transhepatic gallbladder drainage to endoscopic ultrasound-guided hepaticogastrostomy by the intentional expansion method. Digestive Endoscopy, 2019, 31, 718-718.	2.3	1
238	Tu1363 HISTOLOGICAL DIAGNOSIS OF PANCREATIC NEUROENDOCRINE TUMOR USING 25G FNA NEEDLE WITH CORE TRAP: MULTICENTER PROSPECTIVE STUDY. Gastrointestinal Endoscopy, 2019, 89, AB590-AB591.	1.0	0
239	Mo1090 EXAMINATION OF ACTUAL RADIATION EXPOSURE DOSE OF THE PATIENTS WHO PERFORMED EUS-GUIDED DRAINAGE (EUS-BD/EUS-PD/EUS-CD). Gastrointestinal Endoscopy, 2019, 89, AB444-AB445.	1.0	1
240	Tu1384 VALUE OF THE BISPECTRAL INDEX MONITOR DURING ENDOSCOPIC ULTRASONOGRAPHY UNDER SEDATION WITH PROPOFOL AND MIDAZOLAM. Gastrointestinal Endoscopy, 2019, 89, AB602-AB603.	1.0	0
241	Adjuvant therapy after radical surgery for hepatocellular carcinoma: still an unmet need. Hepatobiliary Surgery and Nutrition, 2019, 8, 414-416.	1.5	6
242	Sa1422 THE USEFULNESS OF NOVEL CANNULATION METHOD USING A UNIQUE, DOUBLE LUMENS CATHETER (UNEVEN METHOD) FOR THE PATIENTS WITH SURGICALLY ALTERED GASTROINTESTINAL ANATOMY. Gastrointestinal Endoscopy, 2019, 89, AB223.	1.0	0
243	Large balloon expansion method for re-intervention after endoscopic ultrasound-guided hepaticogastrostomy for stent obstruction. Digestive Endoscopy, 2019, 31, e99-e100.	2.3	4
244	Endoscopic submucosal dissection of duodenal adenocarcinoma arising from Brunner's gland. Annals of Gastroenterology, 2019, 32, 316.	0.6	1
245	New diagnostic technique to evaluate hepatic steatosis using the attenuation coefficient on ultrasound B mode. PLoS ONE, 2019, 14, e0221548.	2.5	29
246	GS-09-Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: Outcomes by liver disease aetiology from two randomised, placebo-controlled phase 3 studies (REACH-2 and REACH). Journal of Hepatology, 2019, 70, e46.	3.7	6
247	Tu1344 VALUE OF CONTRAST-ENHANCED HARMONIC EUS WITH ENHANCEMENT PATTERN FOR DIAGNOSIS OF PANCREATIC CANCER: A META-ANALYSIS. Gastrointestinal Endoscopy, 2019, 89, AB582.	1.0	1
248	FRI-494-Practice patterns and outcomes of transarterial chemoembolization in patients with hepatocellular carcinoma who were ineligible and eligible for transarterial chemoembolization at inclusion: Global OPTIMIS exploratory analysis. Journal of Hepatology, 2019, 70, e616.	3.7	1
249	Combination Cancer Immunotherapy with Molecular Targeted Agents/Anti-CTLA-4 Antibody for Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 1-11.	7.7	48
250	Recent Updates on the Relationship between Cancer and Autoimmune Pancreatitis. Internal Medicine, 2019, 58, 1533-1539.	0.7	29
251	Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α -fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 282-296.	10.7	1,202
252	Intracystic papillary neoplasm preoperatively diagnosed by high-quality cytology derived from endoscopic nasogallbladder drainage. Gastrointestinal Endoscopy, 2019, 89, 1257-1259.	1.0	4

#	ARTICLE	IF	CITATIONS
253	Cabozantinib for advanced hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2019, 8, 153-156.	1.5	2
254	Response Evaluation Criteria in Cancer of the Liver version 5 (RECICL 2019 revised version). Hepatology Research, 2019, 49, 981-989.	3.4	27
255	Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. Journal of Hepatology, 2019, 71, 543-552.	3.7	180
256	PS-136-Can lenvatinib meet clinical needs of patients with unresectable hepatocellular carcinoma? Multicenter analysis. Journal of Hepatology, 2019, 70, e87-e88.	3.7	0
257	RICK/RIP2 is a NOD2-independent nodal point of gut inflammation. International Immunology, 2019, 31, 669-683.	4.0	50
258	Rapid and extensive intrahepatic metastatic recurrence of hepatocellular carcinoma with very small portal vein tumor thrombus after surgery and sustained virological response of HCV with direct-acting antivirals. Pathology International, 2019, 69, 306-308.	1.3	1
259	Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions—Multicenter analysis. Cancer Medicine, 2019, 8, 3719-3728.	2.8	131
260	Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B. Journal of Medical Virology, 2019, 91, 1804-1810.	5.0	28
261	Pembrolizumab for the Treatment of Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 143-154.	7.7	25
262	Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL). Medical Oncology, 2019, 36, 52.	2.5	9
263	A novel technique for stent dysfunction after endoscopic ultrasound-guided hepaticogastrostomy with antegrade stenting. Endoscopy, 2019, 51, E255-E256.	1.8	3
264	Comparison of the Diagnostic Performance of Newly Designed 21-Gauge and Standard 22-Gauge Aspiration Needles in Patients with Solid Pancreatic Masses. Digestive Diseases and Sciences, 2019, 64, 2982-2991.	2.3	3
265	FRI-499-Efficacy and hepatic safety of nivolumab treatment in patients with Child-Pugh B disease and advanced hepatocellular carcinoma in CheckMate 040. Journal of Hepatology, 2019, 70, e619.	3.7	4
266	Contrast-enhanced harmonic endoscopic ultrasonography for evaluating the response to chemotherapy in pancreatic cancer. Digestive and Liver Disease, 2019, 51, 1130-1134.	0.9	9
267	Usefulness of Ustekinumab for Treating a Case of Myelodysplastic Syndrome-associated Inflammatory Bowel Disease. Internal Medicine, 2019, 58, 2029-2033.	0.7	1
268	Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan. Liver Cancer, 2019, 8, 403-411.	7.7	28
269	Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrospective Study. Internal Medicine, 2019, 58, 1993-2002.	0.7	12
270	Objective Response by mRECIST Is an Independent Prognostic Factor of Overall Survival in Systemic Therapy for Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 73-77.	7.7	14

#	ARTICLE	IF	CITATIONS
271	Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan. <i>Journal of Gastroenterology</i> , 2019, 54, 742-751.	5.1	7
272	Novel sphincterotomy device that orientates blade along the axis of the bile duct in patients with Roux-en-Y anastomosis. <i>Endoscopy</i> , 2019, 51, E132-E134.	1.8	4
273	Comparison of the efficacy and safety of endoscopic ultrasound-guided choledochoduodenostomy and hepaticogastrostomy for malignant distal biliary obstruction: Multicenter, randomized, clinical trial. <i>Digestive Endoscopy</i> , 2019, 31, 575-582.	2.3	57
274	Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1192-1200.	4.4	92
275	Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond. <i>World Journal of Gastroenterology</i> , 2019, 25, 789-807.	3.3	135
276	Radiofrequency ablation of liver metastasis: potential impact on immune checkpoint inhibitor therapy. <i>European Radiology</i> , 2019, 29, 5045-5051.	4.5	36
277	RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. <i>Future Oncology</i> , 2019, 15, 1811-1822.	2.4	99
278	Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α -fetoprotein. <i>Lancet Oncology</i> , The, 2019, 20, e191.	10.7	42
279	Current status and perspectives for computer-aided ultrasonic diagnosis of liver lesions using deep learning technology. <i>Hepatology International</i> , 2019, 13, 416-421.	4.2	24
280	Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan. <i>Journal of Gastroenterology</i> , 2019, 54, 558-570.	5.1	59
281	Hepatic portal venous gas associated with <i>Klebsiella oxytoca</i> infection in the absence of preceding antibiotic treatment. <i>Clinical Journal of Gastroenterology</i> , 2019, 12, 316-319.	0.8	13
282	Utility of FIB4-T as a Prognostic Factor for Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 203.	3.7	6
283	Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients. <i>Liver Cancer</i> , 2019, 8, 312-325.	7.7	88
284	Rendezvous within biloma technique combining percutaneous and endoscopic approaches: a novel biliary recanalization method. <i>Endoscopy</i> , 2019, 51, E42-E44.	1.8	2
285	Computer aided diagnosis system developed for ultrasound diagnosis of liver lesions using deep learning. , 2019, , .		15
286	Tu1349 LINEAR EUS TRAINING BY USING SYSTEMATIC SCREENING PROTOCOL FOR THE PANCREATOBILIARY SYSTEM. <i>Gastrointestinal Endoscopy</i> , 2019, 89, AB584.	1.0	0
287	Su1204 ENDOSCOPIC ULTRASOUND-GUDED CHOLEDODUODENOSTOMY USING A THIN STENT DELIVERY SYSTEM IN PATIENTS WITH UNRESECTABLE MALIGNANT DISTAL BILIARY OBSTRUCTION: A PROSPECTIVE MYLTICENTER STUDY. <i>Gastrointestinal Endoscopy</i> , 2019, 89, AB315.	1.0	0
288	Su1172 CLINICAL UTILITY OF ENDOSCOPIC ULTRASOUND-GUIDED DRAINAGE USING CONTRAST-ENHANCED HARMONIC IMAGING IN CASES WITH DIFFICULTIES. <i>Gastrointestinal Endoscopy</i> , 2019, 89, AB299.	1.0	1

#	ARTICLE	IF	CITATIONS
289	Sa1437 A MULTICENTER SINGLE-ARM PROSPECTIVE STUDY TO ASSESS THE UTILITY AND SAFTY OF NOVEL FULLY COVERED METAL STENT FOR OBSTRUCTIVE JAUNDICE IN PATIENTS WITH UNRESECTABLE DISTAL MALIGNANT BILLIARY OBSTRUCTION. Gastrointestinal Endoscopy, 2019, 89, AB230.	1.0	0
290	A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE. Liver Cancer, 2019, 8, 299-311.	7.7	107
291	Su1168 LONG-TERM OUTCOMES OF EUS-GUIDED TRANSLUMINAL STENT DEPLOYEMNT FOR BENIGN BILIARY DISEASE: MULTICENTER CLINICAL EXPERIENCE. Gastrointestinal Endoscopy, 2019, 89, AB297.	1.0	1
292	The IFN- γ -IL-33 Axis as Possible Biomarkers in IgG4-Related Disease. American Journal of Gastroenterology, 2019, 114, 1002-1003.	0.4	7
293	Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies. Liver Cancer, 2019, 8, 413-426.	7.7	40
294	Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial. Liver Cancer, 2019, 8, 505-519.	7.7	20
295	Endoscopic nasobiliary drainage tubeâ€­guided scope insertion technique for internal drainage in a case of difficult selective biliary duct guiding. Digestive Endoscopy, 2019, 31, e1-e2.	2.3	1
296	Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis. Liver Cancer, 2019, 8, 281-294.	7.7	31
297	Hemorrhage from metastasis of a 5-mm renal cell carcinoma lesion to the gallbladder detected by contrast-enhanced endoscopic ultrasonography. Digestive and Liver Disease, 2019, 51, 743.	0.9	2
298	Sorafenib: key lessons from over 10 years of experience. Expert Review of Anticancer Therapy, 2019, 19, 177-189.	2.4	72
299	Novel metallic stent designed for endoscopic bilateral stent-in-stent placement in patients with hilar malignant biliary obstruction. Endoscopy, 2019, 51, E30-E31.	1.8	10
300	Endoscopic ultrasoundâ€­guided choledochoduodenostomy using a thin stent delivery system in patients with unresectable malignant distal biliary obstruction: A prospective multicenter study. Digestive Endoscopy, 2019, 31, 291-298.	2.3	23
301	Liver damage related to immune checkpoint inhibitors. Hepatology International, 2019, 13, 248-252.	4.2	36
302	Efficacy and Safety of Chemotherapy Following Anti-PD-1 Antibody Therapy for Gastric Cancer: A Case of Sclerosing Cholangitis. Internal Medicine, 2019, 58, 1263-1266.	0.7	23
303	Value of contrastâ€­enhanced harmonic endoscopic ultrasonography with enhancement pattern for diagnosis of pancreatic cancer: A metaâ€­analysis. Digestive Endoscopy, 2019, 31, 125-133.	2.3	74
304	Cytokines produced by innate immune cells in IgG4-related disease. Modern Rheumatology, 2019, 29, 219-225.	1.8	14
305	Longâ€­term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion. Hepatology Research, 2019, 49, 594-599.	3.4	25
306	Case of endoscopic ultrasonographyâ€­guided pancreatic duct rendezvous stenting in which initial contrast medium injection was useful for the second puncture. Digestive Endoscopy, 2019, 31, e20-e21.	2.3	0

#	ARTICLE	IF	CITATIONS
307	Impact of Advanced Age on Survival in Patients Undergoing Resection of Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2019, 269, 692-699.	4.2	53
308	Treatment Optimization for Hepatocellular Carcinoma in Elderly Patients in a Japanese Nationwide Cohort. <i>Annals of Surgery</i> , 2019, 270, 121-130.	4.2	48
309	A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small hepatocellular carcinoma (SURF trial).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4002-4002.	1.6	48
310	Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4004-4004.	1.6	149
311	Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4012-4012.	1.6	178
312	First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4072-4072.	1.6	54
313	Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, Tj ETQq1 1 0.784314 rgBT /Overlo		
314	Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS4152-TPS4152.	1.6	94
315	Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT).. <i>Journal of Clinical Oncology</i> , 2019, 37, 186-186.	1.6	35
316	Sorafenib versus hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma: A Japanese multi-center large cohort study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 323-323.	1.6	3
317	Subsequent anticancer medication following first-line lenvatinib: A posthoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 371-371.	1.6	10
318	Effective use of the Japan Narrow Band Imaging Expert Team classification based on diagnostic performance and confidence level. <i>World Journal of Clinical Cases</i> , 2019, 7, 2658-2665.	0.8	13
319	Response Evaluation Criteria in Cancer of the Liver (RECICL 2019 revised version). <i>Acta Hepatologica Japonica</i> , 2019, 60, 55-62.	0.1	10
320	Autoimmune hepatitis and IgG4-related disease. <i>World Journal of Gastroenterology</i> , 2019, 25, 2308-2314.	3.3	32
321	Can Localized Stenosis of the Main Pancreatic Duct be a Predictive Factor for Early Detection of Pancreatic Cancer?. <i>Clinical Endoscopy</i> , 2019, 52, 523-524.	1.5	0
322	Autoimmune Pancreatitis Mouse Model. <i>Current Protocols in Immunology</i> , 2018, 120, 15.31.1-15.31.8.	3.6	9
323	Combination Cancer Immunotherapy in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2018, 7, 20-27.	7.7	55
324	Novel quantitative assessment system of liver steatosis using a newly developed attenuation measurement method. <i>Hepatology Research</i> , 2018, 48, 821-828.	3.4	74

#	ARTICLE	IF	CITATIONS
325	Value of additional endoscopic ultrasonography for surveillance after surgical removal of intraductal papillary mucinous neoplasms. <i>Digestive Endoscopy</i> , 2018, 30, 659-666.	2.3	10
326	Cabozantinib as a Second-Line Agent in Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2018, 7, 123-133.	7.7	20
327	Gastric Inverted Hyperplastic Polyp Mimicking a Papilla. <i>American Journal of Gastroenterology</i> , 2018, 113, 462.	0.4	6
328	Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 424-432.	8.1	216
329	Reintervention for stent occlusion after endoscopic ultrasound-guided hepaticogastrostomy with novel use of a precut needle-knife. <i>Endoscopy</i> , 2018, 50, E153-E154.	1.8	9
330	Sustained Antiviral Effects and Clearance of Hepatitis Surface Antigen after Combination Therapy with Entecavir and Pegylated Interferon in Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2018, 23, 513-521.	1.0	19
331	Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2018, 7, 1-19.	7.7	89
332	Outcomes of endoscopic biliary drainage in pancreatic cancer patients with an indwelling gastroduodenal stent: a multicenter cohort study in West Japan. <i>Gastrointestinal Endoscopy</i> , 2018, 88, 66-75.e2.	1.0	37
333	How to perform Contrast-Enhanced Ultrasound (CEUS). <i>Ultrasound International Open</i> , 2018, 04, E2-E15.	0.6	222
334	Impact of resection and ablation for single hypovascular hepatocellular carcinoma analysed with propensity score weighting. <i>Liver International</i> , 2018, 38, 484-493.	3.9	38
335	Induction of Complete Remission by Azacitidine in a Patient with Myelodysplastic Syndrome-Associated Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 499-502.	1.3	6
336	Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. <i>Lancet</i> , 2018, 391, 1163-1173.	13.7	3,542
337	A case of successful transluminal drainage of walled-off necrosis under contrast-enhanced harmonic endoscopic ultrasonography guidance. <i>Journal of Medical Ultrasonics (2001)</i> , 2018, 45, 161-165.	1.3	6
338	Contrast-enhanced harmonic endoscopic ultrasonography for differential diagnosis of localized gallbladder lesions. <i>Digestive Endoscopy</i> , 2018, 30, 98-106.	2.3	40
339	Impact of avascular areas, as measured by contrast-enhanced harmonic EUS, on the accuracy of FNA for pancreatic adenocarcinoma. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 158-163.	1.0	32
340	Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 37-46.	8.1	127
341	Supplementation of pancreatic digestive enzymes alters the composition of intestinal microbiota in mice. <i>Biochemical and Biophysical Research Communications</i> , 2018, 495, 273-279.	2.1	43
342	Transrectal endoscopic ultrasound-guided paracentesis for diagnosis of malignant ascites in the pelvis. <i>Digestive and Liver Disease</i> , 2018, 50, 311.	0.9	0

#	ARTICLE	IF	CITATIONS
343	Endoscopic ultrasound-guided biliary drainage using a newly designed metal stent with a thin delivery system: a preclinical study in phantom and porcine models. <i>Journal of Medical Ultrasonics</i> (2001), 2018, 45, 391-397.	1.3	9
344	Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial. <i>Journal of Gastroenterology</i> , 2018, 53, 281-290.	5.1	42
345	Recent Advances of Systemic Therapy for Hepatocellular carcinoma. <i>Acta Hepatologica Japonica</i> , 2018, 59, 517-544.	0.1	1
346	Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials. <i>Journal of Global Oncology</i> , 2018, 4, 1-12.	0.5	7
347	Systemic Therapy for Hepatocellular Carcinoma: Recent Advances. <i>Acta Hepatologica Japonica</i> , 2018, 59, 587-603.	0.1	3
348	Erythropoietic Protoporphyrin-related Hepatopathy Successfully Treated with Phlebotomy. <i>Internal Medicine</i> , 2018, 57, 2505-2509.	0.7	7
349	Ramucirumab as Second-Line Systemic Therapy in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2018, 7, 305-311.	7.7	13
350	Molecular Scoring of Hepatocellular Carcinoma for Predicting Metastatic Recurrence and Requirements of Systemic Chemotherapy. <i>Cancers</i> , 2018, 10, 367.	3.7	24
351	Mechanistic Insights into Autoimmune Pancreatitis and IgG4-Related Disease. <i>Trends in Immunology</i> , 2018, 39, 874-889.	6.8	54
352	Systemic Therapy for Hepatocellular Carcinoma: Latest Advances. <i>Cancers</i> , 2018, 10, 412.	3.7	138
353	Extremely High Objective Response Rate of Lenvatinib: Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2018, 7, 215-224.	7.7	56
354	Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. <i>Journal of Hepatology</i> , 2018, 69, 1284-1293.	3.7	360
355	Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients. <i>Investigational New Drugs</i> , 2018, 36, 1072-1084.	2.6	32
356	Liver Ultrasound Elastography: An Update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 2419-2440.	1.5	357
357	Neurilemmoma Mimicking a Multilocular Cystic Lesion of the Liver. <i>Internal Medicine</i> , 2018, 57, 3377-3380.	0.7	3
358	Proposal of Primary Endpoints for TACE Combination Trials with Systemic Therapy: Lessons Learned from 5 Negative Trials and the Positive TACTICS Trial. <i>Liver Cancer</i> , 2018, 7, 225-234.	7.7	35
359	Management of Hepatocellular Carcinoma in Japan as a World-Leading Model. <i>Liver Cancer</i> , 2018, 7, 134-147.	7.7	56
360	Contrast-enhanced Harmonic EUS Imaging of Pancreatic Mucinous Cystadenocarcinoma. <i>Internal Medicine</i> , 2018, 57, 3051-3052.	0.7	0

#	ARTICLE	IF	CITATIONS
361	Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 940-952.	10.7	1,816
362	Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. <i>Cancer Treatment Reviews</i> , 2018, 68, 16-24.	7.7	124
363	Cannulation method for intradiverticular papilla with long oral protrusion using biopsy forceps for axis alignment. <i>Digestive Endoscopy</i> , 2018, 30, 700-701.	2.3	4
364	Dysbiosis-Associated Polyposis of the Colon—Cap Polyposis. <i>Frontiers in Immunology</i> , 2018, 9, 918.	4.8	17
365	Nivolumab-Induced Hemophilia A Presenting as Gastric Ulcer Bleeding in a Patient With NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, e239-e241.	1.1	17
366	Alleviating Pancreatic Cancer-Associated Pain Using Endoscopic Ultrasound-Guided Neurolysis. <i>Cancers</i> , 2018, 10, 50.	3.7	22
367	Immune checkpoint blockade for the treatment of human hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, 622-634.	3.4	58
368	Novel method of biliary cannulation for patients with Roux-Y anastomosis using a unique, uneven, double-lumen cannula (Uneven method). <i>Digestive Endoscopy</i> , 2018, 30, 808-809.	2.3	11
369	Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study. <i>British Journal of Cancer</i> , 2018, 119, 19-26.	6.4	28
370	Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study. <i>Liver Cancer</i> , 2018, 7, 148-164.	7.7	12
371	Acute Pancreatitis with Disturbed Consciousness Caused by Hyperparathyroidism. <i>Internal Medicine</i> , 2018, 57, 3075-3078.	0.7	3
372	A novel biliary cannulation method for difficult cannulation cases using a unique, uneven, double-lumen cannula (Uneven method). <i>Endoscopy</i> , 2018, 50, E229-E230.	1.8	12
373	Dual-energy computed tomography for non-invasive staging of liver fibrosis: Accuracy of iodine density measurements from contrast-enhanced data. <i>Hepatology Research</i> , 2018, 48, 1008-1019.	3.4	45
374	Ultrasound-ultrasound image overlay fusion improves real-time control of radiofrequency ablation margin in the treatment of hepatocellular carcinoma. <i>European Radiology</i> , 2018, 28, 1986-1993.	4.5	36
375	REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4003-4003.	1.6	77
376	Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4017-4017.	1.6	8
377	Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4018-4018.	1.6	65
378	A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4076-4076.	1.6	101

#	ARTICLE	IF	CITATIONS
379	A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma.. Journal of Clinical Oncology, 2018, 36, TPS3110-TPS3110.	1.6	13
380	Randomized, open label, multicenter, phase II trial comparing transarterial chemoembolization (TACE) plus sorafenib with TACE alone in patients with hepatocellular carcinoma (HCC): TACTICS trial.. Journal of Clinical Oncology, 2018, 36, 206-206.	1.6	29
381	KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.. Journal of Clinical Oncology, 2018, 36, 209-209.	1.6	30
382	Independent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) versus sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).. Journal of Clinical Oncology, 2018, 36, 345-345.	1.6	1
383	Deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): An exploratory analysis of OPTIMISâ€”An international observational study assessing the use of sorafenib after TACE.. Journal of Clinical Oncology, 2018, 36, 368-368.	1.6	11
384	Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib.. Journal of Clinical Oncology, 2018, 36, 412-412.	1.6	40
385	Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040.. Journal of Clinical Oncology, 2018, 36, 475-475.	1.6	39
386	A study of ramucirumab (LY3009806) versus placebo in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein (REACH-2).. Journal of Clinical Oncology, 2018, 36, TPS538-TPS538.	1.6	21
387	Nucleotide-binding oligomerization domain 1 and<i>Helicobacter pylori</i>infection: A review. World Journal of Gastroenterology, 2018, 24, 1725-1733.	3.3	20
388	Utility of endoscopic ultrasound in hemorrhage from recurrent duodenal varices. Annals of Gastroenterology, 2018, 31, 636.	0.6	0
389	Cystic duct antegrade stenting for cholangitis after the long-term deployment of lumen-apposing metal stents for calculous cholecystitis. Endoscopic Ultrasound, 2018, 7, 349.	1.5	1
390	5i¼4Žè†³ç,,¶ã...ç—«ãžœãŒEè†µè†“ã®æ...çæŒŒç,Žç—†ã«æžœãŸã™ã¼½¹ã%². Suizo, 2018, 33, 737-742.	0.1	0
391	Stent migration into the abdominal cavity after EUS-guided hepaticogastrostomy. Gastrointestinal Endoscopy, 2017, 85, 263-264.	1.0	31
392	Semiquantitative prediction of early response of conventional transcatheter arterial chemoembolization for hepatocellular carcinoma using postprocedural plain coneâ€”beam computed tomography. Hepatology Research, 2017, 47, E113-E119.	3.4	2
393	Influence of Liver Inflammation on Liver Stiffness Measurement in Patients with Autoimmune Hepatitis Evaluation by Combinational Elastography. Oncology, 2017, 92, 10-15.	1.9	23
394	Magnetic resonance elastography in the assessment of hepatic fibrosis: a study comparing transient elastography and histological data in the same patients. Abdominal Radiology, 2017, 42, 1659-1666.	2.1	17
395	Malignant Transformation of Hepatocellular Adenoma. Oncology, 2017, 92, 16-28.	1.9	12
396	Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. Journal of Hepatology, 2017, 66, 1166-1172.	3.7	178

#	ARTICLE	IF	CITATIONS
397	Contrast-enhanced harmonic endoscopic ultrasonography for differential diagnosis of submucosal tumors of the upper gastrointestinal tract. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1686-1692.	2.8	43
398	Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey. <i>Journal of Gastroenterology</i> , 2017, 52, 1112-1121.	5.1	27
399	Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials. <i>Oncology</i> , 2017, 92, 50-62.	1.9	180
400	Multimaterial Decomposition Algorithm for the Quantification of Liver Fat Content by Using Fast-Kilovolt-Peak Switching Dual-Energy CT: Clinical Evaluation. <i>Radiology</i> , 2017, 283, 108-118.	7.3	78
401	CD68-Positive Cells in Hepatic Angiomyolipoma. <i>Oncology</i> , 2017, 92, 35-39.	1.9	7
402	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. <i>Lancet, The</i> , 2017, 389, 2492-2502.	13.7	3,224
403	Su1307 Outcomes of Biliary Drainage in Pancreatic Cancer Patients With an Indwelling Gastroduodenal Stent: A Multicenter Retrospective Study in West Japan. <i>Gastrointestinal Endoscopy</i> , 2017, 85, AB327-AB328.	1.0	0
404	Cost-effectiveness of EOB-MRI for Hepatocellular Carcinoma in Japan. <i>Clinical Therapeutics</i> , 2017, 39, 738-750.e4.	2.5	18
405	Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: A Japanese nationwide survey. <i>Hepatology</i> , 2017, 66, 510-517.	7.3	135
406	Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications. <i>Liver Cancer</i> , 2017, 6, 204-215.	7.7	159
407	Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment. <i>Liver Cancer</i> , 2017, 6, 16-26.	7.7	97
408	Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 389, 56-66.	13.7	2,771
409	Stress Response Protein RBM3 Promotes the Development of Colitis-associated Cancer. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 57-65.	1.9	17
410	Stress Response Protein RBM3 Promotes the Development of Colitis-associated Cancer. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 66-74.	1.9	5
411	Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. <i>Hepatology International</i> , 2017, 11, 317-370.	4.2	1,537
412	A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib. <i>Liver Cancer</i> , 2017, 6, 177-184.	7.7	40
413	Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. <i>European Journal of Cancer</i> , 2017, 81, 17-25.	2.8	64
414	Rescue EUS-guided intrahepatic biliary drainage for malignant hilar biliary stricture after failed transpapillary re-intervention. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2017, 31, 4764-4772.	2.4	40

#	ARTICLE	IF	CITATIONS
415	Chronic Fibro-Inflammatory Responses in Autoimmune Pancreatitis Depend on IFN- γ and IL-33 Produced by Plasmacytoid Dendritic Cells. <i>Journal of Immunology</i> , 2017, 198, 3886-3896.	0.8	61
416	Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives. <i>Liver Cancer</i> , 2017, 6, 101-112.	7.7	67
417	Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. <i>Investigational New Drugs</i> , 2017, 35, 529-536.	2.6	128
418	MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in Human Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2017, 6, 113-125.	7.7	50
419	Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update. <i>Liver Cancer</i> , 2017, 6, 1-12.	7.7	60
420	Outcome of Combination Therapy with Sofosbuvir and Ledipasvir for Chronic Type C Liver Disease. <i>Oncology</i> , 2017, 92, 3-9.	1.9	12
421	Role of Immune Checkpoint Blockade in the Treatment for Human Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2017, 35, 618-622.	1.9	10
422	Diagnosis of Fibrosis and Activity by a Combined Use of Strain and Shear Wave Imaging in Patients with Liver Disease. <i>Digestive Diseases</i> , 2017, 35, 515-520.	1.9	36
423	Non-Hypervascular Hypointense Hepatic Nodules during the Hepatobiliary Phase of Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced MRI as a Risk Factor of Intrahepatic Distant Recurrence after Radiofrequency Ablation of Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2017, 35, 574-582.	1.9	13
424	Contrast-Enhanced Tissue Harmonic Imaging versus Phase Inversion Harmonic Sonographic Imaging for the Delineation of Hepatocellular Carcinomas. <i>Oncology</i> , 2017, 92, 29-34.	1.9	4
425	Ability of Cytokeratin-18 Fragments and FIB-4 Index to Diagnose Overall and Mild Fibrosis Nonalcoholic Steatohepatitis in Japanese Nonalcoholic Fatty Liver Disease Patients. <i>Digestive Diseases</i> , 2017, 35, 521-530.	1.9	16
426	Serum IFN- γ 3 Levels Correlate with Serum Hepatitis C Virus RNA Levels in Symptomatic Patients with Acute Hepatitis C. <i>Digestive Diseases</i> , 2017, 35, 531-540.	1.9	1
427	Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection. <i>Digestive Diseases</i> , 2017, 35, 565-573.	1.9	13
428	Clinicopathological Study of Autoimmune Hepatitis Cases That Were Difficult to Differentiate from Drug-Induced Liver Injury. <i>Digestive Diseases</i> , 2017, 35, 506-514.	1.9	11
429	Comparison of Sofosbuvir Plus Ribavirin Treatment with Pegylated Interferon Plus Ribavirin Treatment for Chronic Hepatitis C Genotype 2. <i>Digestive Diseases</i> , 2017, 35, 541-547.	1.9	4
430	Hepatocarcinogenesis Is Associated with Serum Albumin Levels after Sustained Virological Responses with Interferon-Based Therapy in Patients with Hepatitis C. <i>Digestive Diseases</i> , 2017, 35, 548-555.	1.9	1
431	Unique Characteristics Associated with Sustained Liver Damage in Chronic Hepatitis C Patients Treated with Direct Acting Antivirals. <i>Digestive Diseases</i> , 2017, 35, 556-564.	1.9	4
432	Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis. <i>Digestive Diseases</i> , 2017, 35, 602-610.	1.9	113

#	ARTICLE	IF	CITATIONS
433	Hemodynamic Changes on Cone-Beam Computed Tomography during Balloon-Occluded Transcatheter Arterial Chemoembolization Using Miriplatin for Hepatocellular Carcinoma: A Preliminary Study. Digestive Diseases, 2017, 35, 598-601.	1.9	4
434	Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2. Digestive Diseases, 2017, 35, 589-597.	1.9	40
435	Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience. Digestive Diseases, 2017, 35, 611-617.	1.9	16
436	Impact of Tumor Factors on Survival in Patients with Hepatocellular Carcinoma Classified Based on Kinki Criteria Stage B2. Digestive Diseases, 2017, 35, 583-588.	1.9	7
437	Endoscopic ultrasound-guided choledochoduodenostomy with novel use of contrast-enhanced harmonic imaging. Endoscopy, 2017, 49, E281-E282.	1.8	4
438	Contribution of C1485T mutation in the HBx gene to human and murine hepatocarcinogenesis. Scientific Reports, 2017, 7, 10440.	3.3	3
439	Gankyrin induces <scp>STAT</scp>3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma. Cancer Science, 2017, 108, 1996-2003.	3.9	40
440	Mo1291 Investigation on the Efficacy of Alteration of Treatment Methods for Difficult Cases in Eus-Bd. Gastrointestinal Endoscopy, 2017, 85, AB493.	1.0	0
441	S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial. The Lancet Gastroenterology and Hepatology, 2017, 2, 407-417.	8.1	51
442	Stent migration during EUS-guided hepaticogastrostomy in a patient with massive ascites: Troubleshooting using additional EUS-guided antegrade stenting. Arab Journal of Gastroenterology, 2017, 18, 120-121.	0.9	10
443	115 Improved Diagnosis of Liver Metastases Using Kupffer-Phase Image of Contrast-Enhanced Harmonic Endoscopic Ultrasonography in Patients With Pancreatic Cancer. Gastrointestinal Endoscopy, 2017, 85, AB53.	1.0	3
444	Su1680 Follow-Up Examination of the Recurrence After Endoscopic Treatment of Colorectal Tumors. Gastrointestinal Endoscopy, 2017, 85, AB392.	1.0	0
445	Portal vein stenting for portal vein stenosis caused by bile duct cancer. Digestive and Liver Disease, 2017, 49, 1282.	0.9	0
446	Albumin-Bilirubin Grade and Hepatocellular Carcinoma Treatment Algorithm. Liver Cancer, 2017, 6, 185-188.	7.7	11
447	Abdominal Ultrasound Findings of Tumor-Forming Hepatic Malignant Lymphoma. Digestive Diseases, 2017, 35, 498-505.	1.9	4
448	Lenvatinib in Advanced Hepatocellular Carcinoma. Liver Cancer, 2017, 6, 253-263.	7.7	43
449	Electronic hydraulic lithotripsy by antegrade digital cholangioscopy through endoscopic ultrasound-guided hepaticojunostomy. Endoscopy, 2017, 49, E316-E318.	1.8	5
450	Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. Liver Cancer, 2017, 6, 325-336.	7.7	202

#	ARTICLE	IF	CITATIONS
451	New Era of the Management of Liver Diseases and Liver Cancer: State-of-the-Art Progress in 2017. Digestive Diseases, 2017, 35, 493-497.	1.9	1
452	The Overall Survival of Patients with Hepatocellular Carcinoma Correlates with the Newly Defined Time to Progression after Transarterial Chemoembolization. Liver Cancer, 2017, 6, 227-235.	7.7	22
453	Utility of contrast-enhanced harmonic EUS for evaluating the effects of steroid therapy in a case of immunoglobulin G4-negative focal autoimmune pancreatitis. Gastrointestinal Endoscopy, 2017, 86, 1177-1179.	1.0	3
454	Immunological Microenvironment of Hepatocellular Carcinoma and Its Clinical Implication. Oncology, 2017, 92, 40-49.	1.9	100
455	Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. Journal of Gastroenterology, 2017, 52, 512-519.	5.1	275
456	Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial. Journal of Gastroenterology, 2017, 52, 494-503.	5.1	39
457	Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma. JAMA Oncology, 2017, 3, 235.	7.1	74
458	The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. Journal of Hepatology, 2017, 66, 338-346.	3.7	299
459	Endoscopic ultrasonography-guided choledochoduodenostomy using a newly designed laser-cut metal stent: Feasibility study in a porcine model. Digestive Endoscopy, 2017, 29, 211-217.	2.3	8
460	New Paradigm in Gastrointestinal Cancer Treatment. Oncology, 2017, 93, 1-8.	1.9	3
461	Characterization of Pancreatic Tumors with Quantitative Perfusion Analysis in Contrast-Enhanced Harmonic Endoscopic Ultrasonography. Oncology, 2017, 93, 55-60.	1.9	22
462	Prophylactic Suturing Closure Is Recommended after Endoscopic Treatment of Colorectal Tumors in Patients with Antiplatelet/Anticoagulant Therapy. Oncology, 2017, 93, 27-29.	1.9	7
463	Magnifying Narrow Band Imaging (NBI) for the Diagnosis of Localized Colorectal Lesions Using the Japan NBI Expert Team (JNET) Classification. Oncology, 2017, 93, 49-54.	1.9	67
464	Hand-Foot Syndrome and Post-Progression Treatment Are the Good Predictors of Better Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Study. Oncology, 2017, 93, 113-119.	1.9	24
465	Clinical Significance of Bmi1 Expression in Inflammatory Bowel Disease. Oncology, 2017, 93, 20-26.	1.9	11
466	Computer-Aided Diagnosis Based on Convolutional Neural Network System for Colorectal Polyp Classification: Preliminary Experience. Oncology, 2017, 93, 30-34.	1.9	167
467	Risk Factors for Postoperative Bleeding in Endoscopic Submucosal Dissection of Colorectal Tumors. Oncology, 2017, 93, 35-42.	1.9	32
468	The Feasibility of 18-mm-Diameter Colonic Stents for Obstructive Colorectal Cancers. Oncology, 2017, 93, 43-48.	1.9	10

#	ARTICLE	IF	CITATIONS
469	Association between the Risk Factors for Pancreatic Ductal Adenocarcinoma and Those for Malignant Intraductal Papillary Mucinous Neoplasm. <i>Oncology</i> , 2017, 93, 102-106.	1.9	10
470	Needle Tract Seeding: An Overlooked Rare Complication of Endoscopic Ultrasound-Guided Fine-Needle Aspiration. <i>Oncology</i> , 2017, 93, 107-112.	1.9	80
471	Primary Hepatic Adenosquamous Carcinoma Associated with Primary Sclerosing Cholangitis. <i>Oncology</i> , 2017, 93, 76-80.	1.9	6
472	A Social Program for the Early Detection of Pancreatic Cancer: The Kishiwada Katsuragi Project. <i>Oncology</i> , 2017, 93, 89-97.	1.9	9
473	Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases. <i>Oncology</i> , 2017, 93, 120-126.	1.9	24
474	Transarterial Chemoembolization in Combination with a Molecular Targeted Agent: Lessons Learned from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2). <i>Oncology</i> , 2017, 93, 127-134.	1.9	59
475	Systemic Therapy for Hepatocellular Carcinoma: 2017 Update. <i>Oncology</i> , 2017, 93, 135-146.	1.9	96
476	Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update. <i>Oncology</i> , 2017, 93, 147-159.	1.9	83
477	Oncogenic Signal and Tumor Microenvironment in Hepatocellular Carcinoma. <i>Oncology</i> , 2017, 93, 160-164.	1.9	56
478	A case of small invasive gastric cancer arising from <i>Helicobacter pylori</i> -negative gastric mucosa: Fundic gland-type adenocarcinoma. <i>JGH Open</i> , 2017, 1, 74-75.	1.6	3
479	Detection of High-Grade Pancreatic Intraepithelial Neoplasia without Morphological Changes of the Main Pancreatic Duct over a Long Period: Importance for Close Follow-Up for Confirmation. <i>Oncology</i> , 2017, 93, 81-86.	1.9	7
480	A Case of Pancreatic Carcinoma in situ Diagnosed by Repeated Pancreatic Juice Cytology. <i>Oncology</i> , 2017, 93, 98-101.	1.9	17
481	Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study. <i>Liver Cancer</i> , 2017, 6, 313-324.	7.7	21
482	Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for <i>Helicobacter pylori</i> . <i>Oncology</i> , 2017, 93, 15-19.	1.9	22
483	Utility of Endoscopic Ultrasound-Guided Hepaticogastrostomy with Antegrade Stenting for Malignant Biliary Obstruction after Failed Endoscopic Retrograde Cholangiopancreatography. <i>Oncology</i> , 2017, 93, 69-75.	1.9	38
484	Clinical Analysis of Esophageal Stricture in Patients Treated with Intralesional Triamcinolone Injection after Endoscopic Submucosal Dissection for Superficial Esophageal Cancer. <i>Oncology</i> , 2017, 93, 9-14.	1.9	13
485	Chronic Pancreatitis Finding by Endoscopic Ultrasonography in the Pancreatic Parenchyma of Intraductal Papillary Mucinous Neoplasms Is Associated with Invasive Intraductal Papillary Mucinous Carcinoma. <i>Oncology</i> , 2017, 93, 61-68.	1.9	15
486	EUS-Guided Pancreatic Duct Drainage for Repeat Pancreatitis in a Patient with Pancreatic Cancer. <i>Oncology</i> , 2017, 93, 87-88.	1.9	5

#	ARTICLE	IF	CITATIONS
487	Evaluation of shear wave dispersion caused by fibrous structure and tissue viscosity using hepatic fibrosis progression and histological models. , 2017, , .		0
488	Evaluation of shear wave dispersion caused by fibrous structure and tissue viscosity using hepatic fibrosis progression and histological models. , 2017, , .		0
489	Efficacy and Safety of Nivolumab in Asian Patients (Pts) With Advanced Hepatocellular Carcinoma (HCC): Subanalysis of the CheckMate 040 Study. Annals of Oncology, 2017, 28, ix87.	1.2	0
490	A New Horizon in Liver Disease. Oncology, 2017, 92, 1-2.	1.9	1
491	Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib. International Journal of Oncology, 2017, 50, 2049-2058.	3.3	15
492	Nucleotide-binding oligomerization domain 1 and gastrointestinal disorders. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 2017, 93, 578-599.	3.8	11
493	Treatment of advanced hepatocellular carcinoma: Future perspective. Annals of Oncology, 2017, 28, ix43.	1.2	0
494	Removal of diminutive colorectal polyps: A prospective randomized clinical trial between cold snare polypectomy and hot forceps biopsy. World Journal of Gastroenterology, 2017, 23, 328.	3.3	44
495	A Case of Type II Enteropathy-Associated T-Cell Lymphoma in a Patient With Ulcerative Colitis. American Journal of Gastroenterology, 2017, 112, 833.	0.4	4
496	Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).. Journal of Clinical Oncology, 2017, 35, 4001-4001.	1.6	65
497	Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.. Journal of Clinical Oncology, 2017, 35, 4013-4013.	1.6	76
498	Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240.. Journal of Clinical Oncology, 2017, 35, TPS4143-TPS4143.	1.6	3
499	Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study.. Journal of Clinical Oncology, 2017, 35, 226-226.	1.6	19
500	Survival by pattern of tumor progression during prior sorafenib (SOR) treatment in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial comparing second-line treatment with regorafenib (REG) or placebo.. Journal of Clinical Oncology, 2017, 35, 229-229.	1.6	9
501	KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma.. Journal of Clinical Oncology, 2017, 35, TPS503-TPS503.	1.6	29
502	KEYNOTE-224: Phase II study of pembrolizumab in patients with previously treated advanced hepatocellular carcinoma.. Journal of Clinical Oncology, 2017, 35, TPS504-TPS504.	1.6	8
503	The oncoprotein gankyrin promotes the development of colitis-associated cancer through activation of STAT3. Oncotarget, 2017, 8, 24762-24776.	1.8	18
504	Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib. Oncotarget, 2017, 8, 36161-36170.	1.8	44

#	ARTICLE	IF	CITATIONS
505	Endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis: Long-term outcomes after removal of a self-expandable metal stent. World Journal of Gastroenterology, 2017, 23, 661.	3.3	53
506	Achievement of long-term stent patency in endoscopic ultrasonography-guided right bile duct drainage after left hepatic lobectomy (with video). Endoscopic Ultrasound, 2017, 6, 412.	1.5	2
507	Endoscopic treatment of tracheoesophageal fistula using the over-the-scope-clip system. Annals of Gastroenterology, 2017, 30, 578.	0.6	11
508	A Case of Waldenstrom Macroglobulinemia with Temporary Appearance of 7S IgM Half Molecule. Clinical Laboratory, 2017, 63, 983-989.	0.5	1
509	New endoscopic ultrasonography techniques for pancreaticobiliary diseases. Ultrasonography, 2016, 35, 169-179.	2.3	19
510	Report of the 19th follow-up survey of primary liver cancer in Japan. Hepatology Research, 2016, 46, 372-390.	3.4	125
511	Reply. Hepatology, 2016, 64, 306-306.	7.3	2
512	Unique features associated with hepatic oxidative DNA damage and DNA methylation in non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1646-1653.	2.8	49
513	US-US Fusion Imaging in Radiofrequency Ablation for Liver Metastases. Digestive Diseases, 2016, 34, 687-691.	1.9	28
514	Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis. Liver Cancer, 2016, 5, 175-189.	7.7	34
515	Outcome of Asunaprevir/Daclatasvir Combination Therapy for Chronic Liver Disease Type C. Digestive Diseases, 2016, 34, 620-626.	1.9	6
516	Cases with Refractory Ascites and a Delayed Response to Tolvaptan. Internal Medicine, 2016, 55, 3273-3277.	0.7	1
517	Hepaticogastrostomy guided by real-time contrast-enhanced harmonic endoscopic ultrasonography: a novel technique. Endoscopy, 2016, 48, E228-E229.	1.8	6
518	Coffee Intake and Liver Enzyme Association in Korean Immigrants and Japanese: A Comprehensive Cross-Sectional Study. Digestive Diseases, 2016, 34, 665-670.	1.9	4
519	Prediction of Embolization Area after Conventional Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Using SYNAPSE VINCENT. Digestive Diseases, 2016, 34, 696-701.	1.9	8
520	Comparison of Contrast-Enhanced Ultrasound and Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced MRI for the Diagnosis of Macroscopic Type of Hepatocellular Carcinoma. Digestive Diseases, 2016, 34, 679-686.	1.9	18
521	Factors predicting through-the-scope gastroduodenal stenting outcomes in patients with gastric outlet obstruction: a large multicenter retrospective study in West Japan. Gastrointestinal Endoscopy, 2016, 84, 757-763.e6.	1.0	41
522	Mo2080 EUS-Guided Intrahepatic Biliary Drainage for Treatment of Obstructive Jaundice in Patients With Malignant Hilar Biliary Stricture After Ineffective or Unsuccessful Transpapillary Approach. Gastrointestinal Endoscopy, 2016, 83, AB521.	1.0	0

#	ARTICLE	IF	CITATIONS
523	Su1681 Removal of Diminutive Colorectal Polyps: A Prospective Randomized Comparative Study between Cold Snare Polypectomy (CSP) and Hot Biopsy Forceps (HBF). <i>Gastrointestinal Endoscopy</i> , 2016, 83, AB392.	1.0	0
524	Gastric Perineurioma. <i>American Journal of Gastroenterology</i> , 2016, 111, 453.	0.4	6
525	Kupffer phase image of Sonazoid-enhanced US is useful in predicting a hypervascularization of non-hypervascular hypointense hepatic lesions detected on Gd-EOB-DTPA-enhanced MRI: a multicenter retrospective study. <i>Journal of Gastroenterology</i> , 2016, 51, 144-152.	5.1	29
526	Acute spinal cord infarction after EUS-guided celiac plexus neurolysis. <i>Gastrointestinal Endoscopy</i> , 2016, 83, 1039-1040.	1.0	23
527	Histologic diagnosis of pancreatic masses using 25-gauge endoscopic ultrasound needles with and without a core trap: a multicenter randomized trial. <i>Endoscopy</i> , 2016, 48, 632-638.	1.8	66
528	Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON. <i>Journal of Gastroenterology</i> , 2016, 51, 1150-1160.	5.1	44
529	Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysis. <i>Medical Oncology</i> , 2016, 33, 114.	2.5	4
530	Bile duct adenoma in patient with chronic hepatitis C: As a benign neoplasm by pathological and imaging studies. <i>Pathology International</i> , 2016, 66, 640-642.	1.3	1
531	Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. <i>Journal of Hepatology</i> , 2016, 65, 1140-1147.	3.7	296
532	Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan. <i>Cancer</i> , 2016, 122, 61-70.	4.1	132
533	Through-the-mesh technique after endoscopic ultrasonography-guided hepaticogastrostomy: a novel re-intervention method. <i>Endoscopy</i> , 2016, 48, E369-E370.	1.8	13
534	IgG4-Related Disease and Innate Immunity. <i>Current Topics in Microbiology and Immunology</i> , 2016, 401, 115-128.	1.1	12
535	Validation of Kinki Criteria, a Modified Substaging System, in Patients with Intermediate Stage Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2016, 34, 671-678.	1.9	22
536	Comparison of Two-Dimensional Shear Wave Elastography and Real-Time Tissue Elastography for Assessing Liver Fibrosis in Chronic Hepatitis B. <i>Digestive Diseases</i> , 2016, 34, 640-649.	1.9	19
537	Clinical Significance of Epigenetic Alterations in Human Hepatocellular Carcinoma and Its Association with Genetic Mutations. <i>Digestive Diseases</i> , 2016, 34, 708-713.	1.9	17
538	Safety, Tolerability, and Efficacy of Sofosbuvir Plus Ribavirin in Elderly Patients Infected with Hepatitis C Virus Genotype 2. <i>Digestive Diseases</i> , 2016, 34, 632-639.	1.9	8
539	Recent Trends in the Management of Hepatocellular Carcinoma with Special Emphasis on Treatment with Regorafenib and Immune Checkpoint Inhibitors. <i>Digestive Diseases</i> , 2016, 34, 714-730.	1.9	7
540	Prospective Risk Analysis of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C by Ultrasound Strain Elastography. <i>Digestive Diseases</i> , 2016, 34, 650-653.	1.9	2

#	ARTICLE	IF	CITATIONS
541	Efficacy and Safety of Sofosbuvir Plus Ribavirin Treatment for Patients with Chronic Hepatitis C Genotype 2. <i>Digestive Diseases</i> , 2016, 34, 627-631.	1.9	4
542	Monoethanolamine Oleate Sclerotherapy for Polycystic Liver Disease. <i>Digestive Diseases</i> , 2016, 34, 654-658.	1.9	5
543	Needle-Tract Seeding on the Proximal Gastric Wall After EUS-Guided Fine-Needle Aspiration of a Pancreatic Mass. <i>American Journal of Gastroenterology</i> , 2016, 111, 1515.	0.4	28
544	Chronic Liver Diseases and Liver Cancer: State-of-the Art Progress in 2016. <i>Digestive Diseases</i> , 2016, 34, 617-619.	1.9	1
545	Radiofrequency Ablation Guided by Contrast-Enhanced Sonography versus B-Mode Sonography for Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization. <i>Digestive Diseases</i> , 2016, 34, 692-695.	1.9	3
546	Feasibility of Extracted-Overlay Fusion Imaging for Intraoperative Treatment Evaluation of Radiofrequency Ablation for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2016, 5, 269-279.	7.7	39
547	Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016, 65, 289-295.	3.7	89
548	Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan. <i>Liver Cancer</i> , 2016, 5, 190-197.	7.7	122
549	Response:. <i>Gastrointestinal Endoscopy</i> , 2016, 83, 1303.	1.0	0
550	371 The Oncoprotein Gankyrin Links Inflammation and Tumorigenesis in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2016, 150, S83.	1.3	2
551	Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. <i>Journal of Hepatology</i> , 2016, 65, 938-943.	3.7	354
552	Tu1351 Prospective Randomized Controlled Study of Helicobacter pylori Eradication in Japan. <i>Gastroenterology</i> , 2016, 150, S881.	1.3	0
553	Predictors of pain response in patients undergoing endoscopic ultrasound-guided neurolysis for abdominal pain caused by pancreatic cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 483-494.	3.2	22
554	Reply. <i>Hepatology</i> , 2016, 63, 1744-1745.	7.3	2
555	Randomized, openâ€label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. <i>Hepatology</i> , 2016, 64, 774-784.	7.3	77
556	Regional differences in sorafenibâ€treated patients with hepatocellular carcinoma: <scp>GIDEON</scp> observational study. <i>Liver International</i> , 2016, 36, 1196-1205.	3.9	44
557	EUS-guided gallbladder drainage for rescue treatment of malignant distal biliary obstruction after unsuccessful ERCP. <i>Gastrointestinal Endoscopy</i> , 2016, 84, 147-151.	1.0	98
558	TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON. <i>Radiology</i> , 2016, 279, 630-640.	7.3	109

#	ARTICLE	IF	CITATIONS
559	Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version). Hepatology Research, 2016, 46, 3-9.	3.4	51
560	Impact of Tight Junction Protein ZO-1 and TWIST Expression on Postoperative Survival of Patients with Hepatocellular Carcinoma. Digestive Diseases, 2016, 34, 702-707.	1.9	13
561	Safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the phase 1/2 CheckMate-040 study.. Journal of Clinical Oncology, 2016, 34, 4078-4078.	1.6	30
562	Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2016, 34, TPS3103-TPS3103.	1.6	5
563	Identification of a high-response patient population to S-1 via predictive enrichment strategy analysis of the S-CUBE phase III trial.. Journal of Clinical Oncology, 2016, 34, 229-229.	1.6	2
564	A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).. Journal of Clinical Oncology, 2016, 34, TPS478-TPS478.	1.6	2
565	Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis. Oncotarget, 2016, 7, 75482-75491.	1.8	18
566	Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative study. Oncotarget, 2016, 7, 44705-44718.	1.8	32
567	Contrast-enhanced harmonic endoscopic ultrasonography for assessment of lymph node metastases in pancreaticobiliary carcinoma. World Journal of Gastroenterology, 2016, 22, 3381-3391.	3.3	37
568	Urgent endoscopic ultrasound-guided choledochoduodenostomy for acute obstructive suppurative cholangitis-induced sepsis. World Journal of Gastroenterology, 2016, 22, 4264.	3.3	18
569	Modified single transluminal gateway transcystic multiple drainage technique for a huge infected walled-off pancreatic necrosis: A case report. World Journal of Gastroenterology, 2016, 22, 5132.	3.3	2
570	Evaluation of anti-migration properties of biliary covered self-expandable metal stents. World Journal of Gastroenterology, 2016, 22, 6917.	3.3	24
571	Endosonography, Contrast Agents, and Elastography. , 2016, , 187-208.		0
572	Regional differences in efficacy/safety/biomarkers in a randomised study of axitinib in 2nd line patients (pts) with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2016, 34, 329-329.	1.6	15
573	A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).. Journal of Clinical Oncology, 2016, 34, TPS4145-TPS4145.	1.6	2
574	Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion: A Japanese nationwide survey.. Journal of Clinical Oncology, 2016, 34, 4067-4067.	1.6	2
575	Impact of vitamin K dosing during sorafenib treatment for hepatocellular carcinoma: Effect on ischemic tumor cell damage caused by sorafenib.. Journal of Clinical Oncology, 2016, 34, e15585-e15585.	1.6	0
576	Tu1664 Quantitative Perfusion Analysis With Contrast-Enhanced Harmonic EUS in Pancreatic Tumors. Gastrointestinal Endoscopy, 2015, 81, AB550.	1.0	1

#	ARTICLE	IF	CITATIONS
577	Synchronous pancreatic and gastric metastasis from an ovarian adenocarcinoma diagnosed by endoscopic ultrasound-guided fine-needle aspiration. <i>Endoscopy</i> , 2015, 47, E596-E597.	1.8	5
578	Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma. <i>Oncology</i> , 2015, 89, 42-46.	1.9	7
579	Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: A Single-Center Experience. <i>Oncology</i> , 2015, 89, 27-32.	1.9	20
580	Contrast-enhanced harmonic endoscopic ultrasonography for pancreatobiliary diseases. <i>Digestive Endoscopy</i> , 2015, 27, 60-67.	2.3	44
581	Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. <i>Liver International</i> , 2015, 35, 2155-2166.	3.9	813
582	Real-Life Clinical Practice with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Center Experience Second Analysis. <i>Digestive Diseases</i> , 2015, 33, 728-734.	1.9	10
583	Validation of a Modified Substaging System (Kinki Criteria) for Patients with Intermediate-Stage Hepatocellular Carcinoma. <i>Oncology</i> , 2015, 89, 47-52.	1.9	31
584	Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2015, 4, 253-262.	7.7	172
585	Challenges of Clinical Research on Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2015, 33, 780-790.	1.9	5
586	Hyperenhanced Rim Surrounding Liver Metastatic Tumors in the Postvascular Phase of Sonazoid-Enhanced Ultrasonography: A Histological Indication of the Presence of Kupffer Cells. <i>Oncology</i> , 2015, 89, 33-41.	1.9	11
587	A Newly Developed Shear Wave Elastography Modality: With a Unique Reliability Index. <i>Oncology</i> , 2015, 89, 53-59.	1.9	27
588	Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2015, 33, 771-779.	1.9	76
589	Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Japanese subgroup analysis of the phase III REACH trial. <i>Annals of Oncology</i> , 2015, 26, vii94.	1.2	0
590	A case of psoriasis vulgaris complicated with antimitochondrial M2 antibody-positive liver dysfunction after infliximab treatment. <i>Acta Hepatologica Japonica</i> , 2015, 56, 655-660.	0.1	1
591	Comparison between T1 relaxation time of Gd-EOB-DTPA-enhanced MRI and liver stiffness measurement of ultrasound elastography in the evaluation of cirrhotic liver. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 41, 329-338.	3.4	12
592	Initial Experience Performing Percutaneous Ultrasound Examination with Real-Time Virtual Sonography with Color Display. <i>Oncology</i> , 2015, 89, 11-18.	1.9	4
593	Response Evaluation Criteria in Cancer of the Liver (RECICL 2015 revised version). <i>Acta Hepatologica Japonica</i> , 2015, 56, 116-121.	0.1	11
594	Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients. <i>Journal of Immunology Research</i> , 2015, 2015, 1-8.	2.2	14

#	ARTICLE	IF	CITATIONS
595	Hepatic DNA Methylation Is Affected by Hepatocellular Carcinoma Risk in Patients with and without Hepatitis Virus. <i>Digestive Diseases</i> , 2015, 33, 745-750.	1.9	9
596	Cold-inducible κ B RNA-binding protein promotes the development of liver cancer. <i>Cancer Science</i> , 2015, 106, 352-358.	3.9	49
597	WFUMB Guidelines and Recommendations for Clinical Use of Ultrasound Elastography: Part 2: Breast. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, 1148-1160.	1.5	368
598	Evidence and Consensus on the Management of Hepatocellular Carcinoma: Update 2015. <i>Oncology</i> , 2015, 89, 1-3.	1.9	8
599	Phase I/II Study of Sorafenib in Combination with Hepatic Arterial Infusion Chemotherapy Using Low-Dose Cisplatin and 5-Fluorouracil. <i>Liver Cancer</i> , 2015, 4, 263-273.	7.7	26
600	Impaired expression of ATP-binding cassette transporter G2 and liver damage in erythropoietic protoporphyria. <i>Hepatology</i> , 2015, 62, 1638-1639.	7.3	9
601	General Rules for the Clinical and Pathological Study of Primary Liver Cancer, Nationwide Follow-Up Survey and Clinical Practice Guidelines: The Outstanding Achievements of the Liver Cancer Study Group of Japan. <i>Digestive Diseases</i> , 2015, 33, 765-770.	1.9	229
602	Evaluation of ART Scores for Repeated Transarterial Chemoembolization in Japanese Patients with Hepatocellular Carcinoma. <i>Oncology</i> , 2015, 89, 4-10.	1.9	21
603	Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria). <i>Digestive Diseases</i> , 2015, 33, 751-758.	1.9	167
604	Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. <i>Annals of Oncology</i> , 2015, 26, 2457-2463.	1.2	85
605	Usefulness of Cytokeratin-18M65 in Diagnosing Non-Alcoholic Steatohepatitis in Japanese Population. <i>Digestive Diseases</i> , 2015, 33, 715-720.	1.9	9
606	Cone-Beam CT Angiography for Hepatocellular Carcinoma: Current Status. <i>Digestive Diseases</i> , 2015, 33, 759-764.	1.9	8
607	Characteristics of Hypovascular versus Hypervascular Well-Differentiated Hepatocellular Carcinoma Smaller Than 2 cm - Focus on Tumor Size, Markers and Imaging Detectability. <i>Digestive Diseases</i> , 2015, 33, 721-727.	1.9	21
608	Contrast-enhanced harmonic endoscopic ultrasonography for differential diagnosis of pancreatic cysts. <i>Endoscopy</i> , 2015, 48, 35-41.	1.8	63
609	Recent Advances in the Management of Chronic Hepatitis B Including Suppression of Hepatocellular Carcinoma by Entecavir and Interferon. <i>Oncology</i> , 2015, 89, 60-69.	1.9	5
610	Early Viral Response Predicts the Efficacy of Antiviral Triple Therapy with Simeprevir, Peg-Interferon and Ribavirin in Patients Infected with Hepatitis C Virus Genotype 1. <i>Digestive Diseases</i> , 2015, 33, 708-714.	1.9	2
611	Percutaneous Radiofrequency Ablation for Intermediate-Stage Hepatocellular Carcinoma. <i>Oncology</i> , 2015, 89, 19-26.	1.9	23
612	Multicenter cooperative case survey of hepatitis B virus reactivation by chemotherapeutic agents. <i>Hepatology Research</i> , 2015, 45, 1220-1227.	3.4	14

#	ARTICLE	IF	CITATIONS
613	Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial. <i>Journal of Gastroenterology</i> , 2015, 50, 667-674.	5.1	36
614	Heat Shock Protein A4 Controls Cell Migration and Gastric Ulcer Healing. <i>Digestive Diseases and Sciences</i> , 2015, 60, 850-857.	2.3	18
615	Surveillance, Diagnosis, Treatment, and Outcome of Liver Cancer in Japan. <i>Liver Cancer</i> , 2015, 4, 39-50.	7.7	175
616	Validation of the Hepatoma Arterial Embolization Prognostic Score in European and Asian Populations and Proposed Modification. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1204-1208.e2.	4.4	53
617	Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 859-870.	10.7	699
618	Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study. <i>Journal of Hepatology</i> , 2015, 63, 896-904.	3.7	44
619	Sa1444 Therapeutic Strategies for Four Subtypes of Laterally Spreading Tumors of the Colorectum. <i>Gastrointestinal Endoscopy</i> , 2015, 81, AB219.	1.0	0
620	Tu1668 Contrast-Enhanced Harmonic Endoscopic Ultrasonography for Diagnosing Cystic Tumors in the Pancreas. <i>Gastrointestinal Endoscopy</i> , 2015, 81, AB552.	1.0	0
621	Value of dynamic contrast enhanced MRI in predicting outcomes of HCC receiving radiotherapy. <i>Hepatology International</i> , 2015, 9, 155-156.	4.2	0
622	WFUMB Guidelines and Recommendations for Clinical Use of Ultrasound Elastography: Part 1: Basic Principles and Terminology. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, 1126-1147.	1.5	718
623	WFUMB Guidelines and Recommendations for Clinical Use of Ultrasound Elastography: Part 3: Liver. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, 1161-1179.	1.5	620
624	Foreword to the WFUMB Guidelines and Recommendations on the Clinical Use of Ultrasound Elastography. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, 1125.	1.5	5
625	Imaging Modalities for Assessment of Treatment Response to Nonsurgical Hepatocellular Carcinoma Therapy: Contrast-Enhanced US, CT, and MRI. <i>Liver Cancer</i> , 2015, 4, 106-114.	7.7	64
626	A Comparison of the Surgical Outcomes Among Patients With HBV-positive, HCV-positive, and Non-B Non-C Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2015, 261, 513-520.	4.2	130
627	Involvement of Heat Shock Protein A4/Apg-2 in Refractory Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 31-39.	1.9	22
628	Plasmacytoid Dendritic Cell Activation and IFN- γ Production Are Prominent Features of Murine Autoimmune Pancreatitis and Human IgG4-Related Autoimmune Pancreatitis. <i>Journal of Immunology</i> , 2015, 195, 3033-3044.	0.8	67
629	Primary leiomyosarcoma of the colon. <i>Clinical Journal of Gastroenterology</i> , 2015, 8, 217-222.	0.8	17
630	Evidence-based clinical practice guidelines for hepatocellular carcinoma: The Japanese Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). <i>Hepatology Research</i> , 2015, 45, .	3.4	339

#	ARTICLE	IF	CITATIONS
631	The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology, 2015, 62, 440-451.	7.3	310
632	Percutaneous endoscopic gastrostomy with Funada-style gastropexy greatly reduces the risk of peristomal infection. Gastroenterology Report, 2015, 3, 69-74.	1.3	22
633	Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncology, The, 2015, 16, 1344-1354.	10.7	809
634	Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial. Journal of Clinical Oncology, 2015, 33, 172-179.	1.6	517
635	Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer. Cancer Letters, 2015, 356, 819-827.	7.2	75
636	Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. Journal of Gastroenterology, 2015, 50, 191-202.	5.1	76
637	A randomized, double-blind, placebo-controlled phase III study of S-1 in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE).. Journal of Clinical Oncology, 2015, 33, 4018-4018.	1.6	5
638	Sorafenib plus intra-arterial cisplatin versus sorafenib alone in patients with advanced hepatocellular carcinoma: A randomized phase II trial.. Journal of Clinical Oncology, 2015, 33, 4076-4076.	1.6	2
639	Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study.. Journal of Clinical Oncology, 2015, 33, 4077-4077.	1.6	3
640	Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated α -fetoprotein (AFP) from the randomized phase III REACH study.. Journal of Clinical Oncology, 2015, 33, 232-232.	1.6	14
641	Phase II study of front-line dovitinib (TKI258) versus sorafenib in patients (Pts) with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2015, 33, 237-237.	1.6	5
642	Antiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferon. World Journal of Hepatology, 2015, 7, 2427.	2.0	14
643	Objective response by mRECIST to predict survival in hepatocellular carcinoma: A multivariate, time-dependent analysis from the phase III BRISK-PS study.. Journal of Clinical Oncology, 2015, 33, 4084-4084.	1.6	0
644	Prognostic subclassification of Intermediate Hepatocellular Carcinoma (I-HCC): a multicentre cohort study with propensity score analysis.. Journal of Clinical Oncology, 2015, 33, e15139-e15139.	1.6	0
645	Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of Liver Cancer Study Group of Japan.. Journal of Clinical Oncology, 2015, 33, 4075-4075.	1.6	0
646	Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of REACH pts by Child-Pugh (CP) score.. Journal of Clinical Oncology, 2015, 33, 4108-4108.	1.6	0
647	Abstract CT120: Axitinib safety and pharmacokinetics in Child-Pugh A and Child-Pugh B patients with advanced hepatocellular cancer. , 2015, , .		0
648	Validation of Three Staging Systems for Hepatocellular Carcinoma (IIS Score, Biomarker-Combined IIS) Tj ETQq0 0 0 rgBT /Overlock 10 T 717-724.	1.9	26

#	ARTICLE	IF	CITATIONS
649	Decreased Blood Flow after Sorafenib Administration Is an Imaging Biomarker to Predict Overall Survival in Patients with Advanced Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2014, 32, 733-739.	1.9	7
650	Identification of Epigenetically Inactivated Genes in Human Hepatocellular Carcinoma by Integrative Analyses of Methylation Profiling and Pharmacological Unmasking. <i>Digestive Diseases</i> , 2014, 32, 740-746.	1.9	12
651	Radiofrequency Ablation for Hepatocellular Carcinoma Measuring 2 cm or Smaller: Results and Risk Factors for Local Recurrence. <i>Digestive Diseases</i> , 2014, 32, 670-677.	1.9	27
652	Ultrasound Fusion Imaging of Hepatocellular Carcinoma: A Review of Current Evidence. <i>Digestive Diseases</i> , 2014, 32, 690-695.	1.9	34
653	Pathological Diagnosis of Benign Hepatocellular Nodular Lesions Based on the New World Health Organization Classification. <i>Oncology</i> , 2014, 87, 37-49.	1.9	18
654	Surveillance and Diagnostic Algorithm for Hepatocellular Carcinoma Proposed by the Liver Cancer Study Group of Japan: 2014 Update. <i>Oncology</i> , 2014, 87, 7-21.	1.9	73
655	JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. <i>Liver Cancer</i> , 2014, 3, 458-468.	7.7	512
656	Accuracy of Real-Time Tissue Elastography for the Evaluation of Hepatic Fibrosis in Patients with Chronic Hepatitis B: A Prospective Multicenter Study. <i>Digestive Diseases</i> , 2014, 32, 791-799.	1.9	14
657	Ultrasound Elastography Correlates Treatment Response by Antiviral Therapy in Patients with Chronic Hepatitis C. <i>Oncology</i> , 2014, 87, 118-123.	1.9	17
658	Recent Progress in Radiofrequency Ablation Therapy for Hepatocellular Carcinoma. <i>Oncology</i> , 2014, 87, 73-77.	1.9	28
659	Quantitative Levels of Hepatitis B Virus DNA and Surface Antigen and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Receiving Long-Term Nucleos(t)ide Analogue Therapy. <i>Liver Cancer</i> , 2014, 3, 41-52.	7.7	48
660	Combination Guidance of Contrast-Enhanced US and Fusion Imaging in Radiofrequency Ablation for Hepatocellular Carcinoma with Poor Conspicuity on Contrast-Enhanced US/Fusion Imaging. <i>Oncology</i> , 2014, 87, 55-62.	1.9	46
661	Genome-Wide Profiling of DNA Methylation and Tumor Progression in Human Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2014, 32, 658-663.	1.9	25
662	Reply to Kadayifci and Brugge. <i>Endoscopy</i> , 2014, 46, 358-358.	1.8	0
663	Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms. <i>Endoscopy</i> , 2014, 46, 358-358.	1.8	12
664	Contrast-enhanced endoscopic ultrasound. <i>Digestive Endoscopy</i> , 2014, 26, 79-85.	2.3	44
665	NOD2 downregulates colonic inflammation by IRF4-mediated inhibition of K63-linked polyubiquitination of RICK and TRAF6. <i>Mucosal Immunology</i> , 2014, 7, 1312-1325.	6.0	62
666	Serum amyloid A and C-reactive protein positive nodule in alcoholic liver cirrhosis, hard to make definite diagnosis. <i>Hepatology Research</i> , 2014, 44, 584-590.	3.4	9

#	ARTICLE	IF	CITATIONS
667	Stress Response Protein Cirp Links Inflammation and Tumorigenesis in Colitis-Associated Cancer. Cancer Research, 2014, 74, 6119-6128.	0.9	64
668	Dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma: a prospective study. Alimentary Pharmacology and Therapeutics, 2014, 40, 1270-1281.	3.7	30
669	Nationwide survey in Japan regarding splenectomy/partial splenic embolization for interferon treatment targeting hepatitis C virus-related chronic liver disease in patients with low platelet count. Hepatology Research, 2014, 44, 829-836.	3.4	7
670	Current treatment status of polycystic liver disease in Japan. Hepatology Research, 2014, 44, 1110-1118.	3.4	19
671	Endoscopic ultrasonography-guided gallbladder drainage procedures: is the glass half full or half empty?. Digestive Endoscopy, 2014, 26, 636-637.	2.3	0
672	Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatology Research, 2014, 44, 73-82.	3.4	128
673	Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel. Liver International, 2014, 34, 174-183.	3.9	68
674	Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial. Hepatology, 2014, 60, 1697-1707.	7.3	279
675	Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib. JAMA - Journal of the American Medical Association, 2014, 312, 57.	7.4	515
676	Treatment Strategies of Intermediate-Stage Hepatocellular Carcinomas in Japan (Barcelona Clinic Liver) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.9	14
677	Noninvasive Diagnosis of Liver Fibrosis: Utility of Data Mining of Both Ultrasound Elastography and Serological Findings to Construct a Decision Tree. Oncology, 2014, 87, 63-72.	1.9	12
678	Prognostic Impact of Spontaneous Tumor Rupture in Patients With Hepatocellular Carcinoma. Annals of Surgery, 2014, 259, 532-542.	4.2	145
679	Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update. Oncology, 2014, 87, 22-31.	1.9	216
680	Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma. Journal of Gastroenterology, 2014, 49, 1578-1587.	5.1	37
681	The gross classification of hepatocellular carcinoma: Usefulness of contrast-enhanced US. Journal of Clinical Ultrasound, 2014, 42, 1-8.	0.8	25
682	Duration of Stable Disease Is Associated with Overall Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. Digestive Diseases, 2014, 32, 705-710.	1.9	17
683	Clinical Features of Vascular Disorders Associated with Chronic Hepatitis Virus Infection. Digestive Diseases, 2014, 32, 786-790.	1.9	10
684	Emerging Strategies for the Management of Hepatocellular Carcinoma. Digestive Diseases, 2014, 32, 655-657.	1.9	3

#	ARTICLE	IF	CITATIONS
685	<sc>GIDEON</sc> (Global Investigation of therapeutic <sc>DE</sc> cisions in hepatocellular) Tj ETQq1 1 0.784314 rgBT /Overlock Clinical Practice, 2014, 68, 609-617.	1.7	215
686	Assessment for retreatment (ART) score for repeated transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology, 2014, 59, 2424-2425.	7.3	37
687	Relevance of the Core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a±Aribavirin for chronic hepatitis C of Genotype 1b: a multicenter randomized trial, ReGIT-J study. Journal of Gastroenterology, 2014, 49, 492-501.	5.1	5
688	Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer. Molecular Cancer, 2014, 13, 126.	19.2	31
689	Virtual Sonography for Novice Sonographers: Usefulness of SYNAPSE VINCENTÂ® with Pre-Check Imaging of Tumor Location. Oncology, 2014, 87, 50-54.	1.9	7
690	Alteration of Epigenetic Profile in Human Hepatocellular Carcinoma and Its Clinical Implications. Liver Cancer, 2014, 3, 417-427.	7.7	38
691	Efficacy and Safety of Telaprevir-Based Antiviral Treatment for Elderly Patients with Hepatitis C Virus. Oncology, 2014, 87, 110-117.	1.9	3
692	Tracking Navigation Imaging of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Using Three-Dimensional Cone-Beam CT Angiography. Liver Cancer, 2014, 3, 53-61.	7.7	59
693	Impact of Histologically Confirmed Lymph Node Metastases on Patient Survival After Surgical Resection for Hepatocellular Carcinoma. Annals of Surgery, 2014, 259, 166-170.	4.2	52
694	Nationwide Study of 4741 Patients With Non-B Non-C Hepatocellular Carcinoma With Special Reference to the Therapeutic Impact. Annals of Surgery, 2014, 259, 336-345.	4.2	62
695	Validation of the Criteria of Transcatheter Arterial Chemoembolization Failure or Refractoriness in Patients with Advanced Hepatocellular Carcinoma Proposed by the LCSCJ. Oncology, 2014, 87, 32-36.	1.9	45
696	Prognostic and predictive role of circulating angiopoietin-2 in multiple solid tumors: An analysis of approximately 500 patients treated with lenvatinib across tumor types.. Journal of Clinical Oncology, 2014, 32, 11061-11061.	1.6	2
697	STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC). Journal of Clinical Oncology, 2014, 32, 4006-4006.	1.6	38
698	Randomized phase II trial of intravenous RO5137382/GC33 at 1600 mg every other week and placebo in previously treated patients with unresectable advanced hepatocellular carcinoma (HCC;) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 505217 Td (N	1.6	10
699	A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma.. Journal of Clinical Oncology, 2014, 32, TPS4153-TPS4153.	1.6	9
700	OPTIMIS: An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2014, 32, TPS4155-TPS4155.	1.6	4
701	EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib.. Journal of Clinical Oncology, 2014, 32, 172-172.	1.6	26
702	Therapeutic response assessment of RFA for HCC: Contrast-enhanced US, CT and MRI. World Journal of Gastroenterology, 2014, 20, 4160.	3.3	62

#	ARTICLE	IF	CITATIONS
703	Multicenter observational study of reactivation of hepatitis B virus (HBV) caused by chemotherapy for solid tumors (ST).. Journal of Clinical Oncology, 2014, 32, 1590-1590.	1.6	0
704	Inhibition of hepatocellular carcinoma by PegIFN α -2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study. Journal of Gastroenterology, 2013, 48, 382-390.	5.1	21
705	Toll-like receptor activation in basophils contributes to the development of IgG4-related disease. Journal of Gastroenterology, 2013, 48, 247-253.	5.1	97
706	Diagnostic value of endoscopic ultrasound-guided directional eFLOW in solid pancreatic lesions. Journal of Medical Ultrasonics (2001), 2013, 40, 211-218.	1.3	13
707	Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver “ Update 2012. Ultrasound in Medicine and Biology, 2013, 39, 187-210.	1.5	652
708	Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (<sc>EPOIHCC</sc>). Liver International, 2013, 33, 327-337.	3.9	70
709	Oxidative Stress and Epigenetic Instability in Human Hepatocarcinogenesis. Digestive Diseases, 2013, 31, 447-453.	1.9	67
710	JSUM ultrasound elastography practice guidelines: liver. Journal of Medical Ultrasonics (2001), 2013, 40, 325-357.	1.3	89
711	Association of Gankyrin and Stemness Factor Expression in Human Colorectal Cancer. Digestive Diseases and Sciences, 2013, 58, 2337-2344.	2.3	25
712	Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study. Journal of Clinical Oncology, 2013, 31, 3517-3524.	1.6	675
713	Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial. Journal of Clinical Oncology, 2013, 31, 4067-4075.	1.6	678
714	Factors of Response to Pegylated Interferon/Ribavirin Combination Therapy and Mechanism of Viral Clearance. Digestive Diseases, 2013, 31, 421-425.	1.9	2
715	Prediction of Response to Pegylated Interferon/Ribavirin Combination Therapy for Chronic Hepatitis C Genotypes 2a and 2b and High Viral Load. Digestive Diseases, 2013, 31, 426-433.	1.9	3
716	Corrigendum to: “Comparison of resection and ablation for hepatocellular carcinoma: A cohort study based on a Japanese nationwide survey” [J Hepatol 2013;58:724-729]. Journal of Hepatology, 2013, 59, 641.	3.7	3
717	Corrigendum to “Estimation of liver function using T2* mapping on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging” [Eur. J. Radiol. 81 (7) (2012) 1460-1464]. European Journal of Radiology, 2013, 82, 1039.	2.6	0
718	A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. European Journal of Cancer, 2013, 49, 2832-2840.	2.8	33
719	Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study. Journal of Clinical Oncology, 2013, 31, 3509-3516.	1.6	544
720	Assessment of Liver Fibrosis with Real-Time Tissue Elastography in Chronic Viral Hepatitis. Oncology, 2013, 84, 13-20.	1.9	66

#	ARTICLE	IF	CITATIONS
721	Novel Image Analysis Method Using Ultrasound Elastography for Noninvasive Evaluation of Hepatic Fibrosis in Patients with Chronic Hepatitis C. <i>Oncology</i> , 2013, 84, 3-12.	1.9	66
722	Recent Advancements in Comprehensive Genetic Analyses for Human Hepatocellular Carcinoma. <i>Oncology</i> , 2013, 84, 93-97.	1.9	56
723	Clinical implication of hypovascular hepatocellular carcinoma studied in 4,474 patients with solitary tumour equal or less than 3Âcm. <i>Liver International</i> , 2013, 33, 762-770.	3.9	52
724	Expression of E-Cadherin and Vascular Endothelial Growth Factor in Noncancerous Liver Is Associated with Recurrence of Hepatocellular Carcinoma after Curative Resection. <i>Oncology</i> , 2013, 84, 88-92.	1.9	8
725	Role of Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced Magnetic Resonance Imaging in the Management of Hepatocellular Carcinoma: Consensus at the Symposium of the 48th Annual Meeting of the Liver Cancer Study Group of Japan. <i>Oncology</i> , 2013, 84, 21-27.	1.9	30
726	Comparison of resection and ablation for hepatocellular carcinoma: A cohort study based on a Japanese nationwide survey. <i>Journal of Hepatology</i> , 2013, 58, 724-729.	3.7	322
727	FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. <i>Hepatology</i> , 2013, 57, 1407-1415.	7.3	133
728	Heat Shock Protein 27 Expression is Inversely Correlated with Atrophic Gastritis and Intraepithelial Neoplasia. <i>Digestive Diseases and Sciences</i> , 2013, 58, 381-388.	2.3	12
729	Autoimmune Hepatitis and Immunoglobulin G4-Associated Autoimmune Hepatitis. <i>Digestive Diseases</i> , 2013, 31, 415-420.	1.9	29
730	Advances in Liver Fibrosis Imaging and Hepatocellular Carcinoma: Update in 2013. <i>Oncology</i> , 2013, 84, 1-2.	1.9	4
731	Usefulness of Contrast-Enhanced Ultrasonography to Evaluate the Post-Treatment Responses of Radiofrequency Ablation for Hepatocellular Carcinoma: Comparison with Dynamic CT. <i>Oncology</i> , 2013, 84, 51-57.	1.9	39
732	The Prognostic Value of Vascular Endothelial Growth Factor in Hepatocellular Carcinoma for Predicting Metastasis after Curative Resection. <i>Oncology</i> , 2013, 84, 75-81.	1.9	20
733	Quantification of Tumor DNA in Serum and Vascular Invasion of Human Hepatocellular Carcinoma. <i>Oncology</i> , 2013, 84, 82-87.	1.9	12
734	Hypovascular Nodules in Patients with Chronic Liver Disease: Risk Factors for Development of Hypervascular Hepatocellular Carcinoma. <i>Radiology</i> , 2013, 266, 480-490.	7.3	126
735	p38Î± Inhibits Liver Fibrogenesis and Consequent Hepatocarcinogenesis by Curtailing Accumulation of Reactive Oxygen Species. <i>Cancer Research</i> , 2013, 73, 215-224.	0.9	65
736	Hypothermia Protects against Fulminant Hepatitis in Mice by Reducing Reactive Oxygen Species Production. <i>Digestive Diseases</i> , 2013, 31, 440-446.	1.9	23
737	Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver â€“ Update 2012. <i>Ultraschall in Der Medizin</i> , 2013, 34, 11-29.	1.5	470
738	Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms. <i>Endoscopy</i> , 2013, 46, 22-29.	1.8	104

#	ARTICLE	IF	CITATIONS
739	Radiofrequency Ablation of Liver Metastases from Colorectal Cancer: A Literature Review. Gut and Liver, 2013, 7, 1-6.	2.9	66
740	Novel Mouse Models of Hepatocarcinogenesis with Stepwise Accumulation of Genetic Alterations. Digestive Diseases, 2013, 31, 454-458.	1.9	3
741	Usefulness of the Extracted-Overlay Function in CT/MR-Ultrasonography Fusion Imaging for Radiofrequency Ablation of Hepatocellular Carcinoma. Digestive Diseases, 2013, 31, 485-489.	1.9	11
742	Therapeutic Response Assessment of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: Ultrasonography, CT and MR Imaging. Oncology, 2013, 84, 58-63.	1.9	24
743	Outcome of Double-Filtration Plasmapheresis plus Interferon Treatment in Nonresponders to Pegylated Interferon plus Ribavirin Combination Therapy. Digestive Diseases, 2013, 31, 434-439.	1.9	5
744	Molecular Link between Liver Fibrosis and Hepatocellular Carcinoma. Liver Cancer, 2013, 2, 365-366.	7.7	50
745	Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B. Journal of Medical Virology, 2013, 85, 987-995.	5.0	19
746	Senile systemic amyloidosis localized to the stomach. Digestive Endoscopy, 2013, 25, 468-469.	2.3	3
747	Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. British Journal of Cancer, 2013, 109, 1904-1907.	6.4	132
748	Clinical and Histological Features of Different Types of Budd-Chiari Syndrome: A Comparison of 4 Cases. Digestive Diseases, 2013, 31, 408-414.	1.9	6
749	Reactive Oxygen Species Induce Epigenetic Instability through the Formation of 8-Hydroxydeoxyguanosine in Human Hepatocarcinogenesis. Digestive Diseases, 2013, 31, 459-466.	1.9	82
750	CD34 Expression in Noncancerous Liver Tissue Predicts Multicentric Recurrence of Hepatocellular Carcinoma. Digestive Diseases, 2013, 31, 467-471.	1.9	10
751	Hypovascular Hepatic Nodules Showing Hypointense on the Hepatobiliary-Phase Image of Gd-EOB-DTPA-Enhanced MRI to Develop a Hypervascular Hepatocellular Carcinoma: A Nationwide Retrospective Study on Their Natural Course and Risk Factors. Digestive Diseases, 2013, 31, 472-479.	1.9	38
752	Radiofrequency Ablation for Hepatic Malignancies: Is Needle Tract Cauterization Necessary for Preventing Iatrogenic Bleeding?. Digestive Diseases, 2013, 31, 480-484.	1.9	9
753	Hepatocellular Carcinoma in Child-Pugh C Cirrhosis: Prognostic Factors and Survival Benefit of Nontransplant Treatments. Digestive Diseases, 2013, 31, 490-498.	1.9	25
754	Unique Association between Global DNA Hypomethylation and Chromosomal Alterations in Human Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e72312.	2.5	31
755	Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2013, 31, 249-249.	1.6	43
756	Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers. World Journal of Gastroenterology, 2013, 19, 5706.	3.3	18

#	ARTICLE	IF	CITATIONS
757	Plasma Concentrations of Angiogenesis-related Molecules in Patients with Pancreatic Cancer. Japanese Journal of Clinical Oncology, 2012, 42, 105-112.	1.3	19
758	Retreatment with Peginterferon a-2a + Ribavirin in Patients Who Failed Previous Peginterferon a-2b + Ribavirin Combination Therapy. Digestive Diseases, 2012, 30, 554-560.	1.9	2
759	Characterization of Small Solid Tumors in the Pancreas: The Value of Contrast-Enhanced Harmonic Endoscopic Ultrasonography. American Journal of Gastroenterology, 2012, 107, 303-310.	0.4	282
760	Gender Differences in the Livers of Patients with Hepatocellular Carcinoma and Chronic Hepatitis C Infection. Digestive Diseases, 2012, 30, 547-553.	1.9	9
761	Novel Non-Trocar Technique for Laparoscopic Radiofrequency Ablation. Digestive Diseases, 2012, 30, 588-591.	1.9	2
762	Viral Hepatitis and Hepatocellular Carcinoma: Update in 2012. Digestive Diseases, 2012, 30, 539-540.	1.9	0
763	Risk of Hepatocellular Carcinoma Development in Cases of Hepatitis C Treated by Long-Term, Low-Dose PEG-IFN α -2a. Digestive Diseases, 2012, 30, 561-567.	1.9	2
764	Histopathological Diagnosis of Early HCC through Biopsy: Efficacy of Victoria Blue and Cytokeratin 7 Staining. Digestive Diseases, 2012, 30, 574-579.	1.9	12
765	Hepatocellular Carcinoma with Obstructive Jaundice: Endoscopic and Percutaneous Biliary Drainage. Digestive Diseases, 2012, 30, 592-597.	1.9	16
766	Real-Life Clinical Practice with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Center Experience. Digestive Diseases, 2012, 30, 609-616.	1.9	24
767	Targeted Therapy for Liver Cancer: Updated Review in 2012. Current Cancer Drug Targets, 2012, 12, 1062-1072.	1.6	3
768	Well-differentiated Hepatocellular Carcinoma Detected as Hypovascularity by Only CT during Hepatic Arteriography. Internal Medicine, 2012, 51, 885-890.	0.7	2
769	Hepatic Nodules Associated with an Inferior Mesenteric Arteriovenous Malformation. Internal Medicine, 2012, 51, 2753-2755.	0.7	4
770	Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma. British Journal of Cancer, 2012, 106, 1997-2003.	6.4	96
771	A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriaplatin) for hepatocellular carcinoma. Investigational New Drugs, 2012, 30, 2015-2025.	2.6	31
772	Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT. Journal of Gastroenterology, 2012, 47, 1036-1047.	5.1	77
773	Sensing of Commensal Organisms by the Intracellular Sensor NOD1 Mediates Experimental Pancreatitis. Immunity, 2012, 37, 326-338.	14.3	84
774	Endoscopic Ultrasound: Contrast Enhancement. Gastrointestinal Endoscopy Clinics of North America, 2012, 22, 349-358.	1.4	33

#	ARTICLE	IF	CITATIONS
775	Can the biliary enhancement of Gd-EOB-DTPA predict the degree of liver function?. Hepatobiliary and Pancreatic Diseases International, 2012, 11, 307-313.	1.3	12
776	Mechanical Model Analysis for Quantitative Evaluation of Liver Fibrosis Based on Ultrasound Tissue Elasticity Imaging. Japanese Journal of Applied Physics, 2012, 51, 07GF11.	1.5	18
777	Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. Journal of Hepatology, 2012, 56, 886-892.	3.7	191
778	Treatment response assessment of radiofrequency ablation for hepatocellular carcinoma: Usefulness of virtual CT sonography with magnetic navigation. European Journal of Radiology, 2012, 81, e277-e280.	2.6	22
779	Estimation of liver function using T2* mapping on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging. European Journal of Radiology, 2012, 81, 1460-1464.	2.6	34
780	Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. Hepatology, 2012, 56, 994-1003.	7.3	129
781	Case of <sc>P</sc>eutzâ€<sc>J</sc>eghers syndrome with depressedâ€type early duodenal carcinoma. Digestive Endoscopy, 2012, 24, 489-489.	2.3	1
782	Characteristic Pattern of Reactivation of Hepatitis B Virus during Chemotherapy for Solid Cancers. Digestive Diseases, 2012, 30, 541-546.	1.9	17
783	Transcatheter endoscopy for pancreaticobiliary duct diseases (with videos). Gastrointestinal Endoscopy, 2012, 76, 892-899.	1.0	3
784	Septicemia due to Vibrio cholerae serogroup non-O1/non-O139 strain in a cirrhotic patient. Clinical Journal of Gastroenterology, 2012, 5, 383-387.	0.8	3
785	Treatment of Advanced Hepatocellular Carcinoma with Emphasis on Hepatic Arterial Infusion Chemotherapy and Molecular Targeted Therapy. Liver Cancer, 2012, 1, 62-70.	7.7	103
786	p38MAPK suppresses chronic pancreatitis by regulating HSP27 and BAD expression. Free Radical Biology and Medicine, 2012, 52, 2284-2291.	2.9	7
787	First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular) Tj ETQq1 1 0.784314 rgBT /Over Clinical Practice, 2012, 66, 675-683.	1.7	102
788	Activation of câ€Jun Nâ€terminal kinase in nonâ€cancerous liver tissue predicts a high risk of recurrence after hepatic resection for hepatocellular carcinoma. Hepatology Research, 2012, 42, 394-400.	3.4	8
789	Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update. Hepatology Research, 2012, 42, 523-542.	3.4	41
790	Involvement of activation of Tollâ€like receptors and nucleotideâ€binding oligomerization domainâ€like receptors in enhanced IgG4 responses in autoimmune pancreatitis. Arthritis and Rheumatism, 2012, 64, 914-924.	6.7	126
791	Quantification of tumor vascularity with contrast-enhanced ultrasound for early response of transcatheter arterial chemoembolization for hepatocellular carcinoma: a report of three cases. Journal of Medical Ultrasonics (2001), 2012, 39, 15-19.	1.3	4
792	Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC bridge study: First characterization of the full study population.. Journal of Clinical Oncology, 2012, 30, 4033-4033.	1.6	11

#	ARTICLE	IF	CITATIONS
793	Second interim analysis of the Global Investigation of Therapeutic Decisions in Unresectable HCC (uHCC) and of Its Treatment with Sorafenib (GIDEON): Differences in AE reporting across physician specialties.. Journal of Clinical Oncology, 2012, 30, 286-286.	1.6	1
794	Worldwide trends in locoregional therapy for hepatocellular carcinoma (HCC): Second interim analysis of the Global Investigation of Therapeutic Decisions in HCC and of Its Treatment with Sorafenib (GIDEON) study.. Journal of Clinical Oncology, 2012, 30, 317-317.	1.6	1
795	Phase I/II study of E7080 (lenvatinib), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Initial assessment of response rate.. Journal of Clinical Oncology, 2012, 30, 320-320.	1.6	6
796	Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma. World Journal of Gastroenterology, 2012, 18, 6005.	3.3	39
797	Mechanical Model Analysis for Quantitative Evaluation of Liver Fibrosis Based on Ultrasound Tissue Elasticity Imaging. Japanese Journal of Applied Physics, 2012, 51, 07GF11.	1.5	5
798	Abstract 3406: Impact of TJP-1 and TWIST expression on post-operative prognosis in hepatocellular carcinoma. , 2012, , .		1
799	Phase Ib dose-escalation study of a phase II randomized trial to assess the safety and tolerability of tigatuzumab (CS-1008) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2012, 30, e14617-e14617.	1.6	0
800	Current Status of Hepatocellular Carcinoma Treatment in Japan. Clinical Drug Investigation, 2012, 32, 37-51.	2.2	5
801	Closing Remarks. Clinical Drug Investigation, 2012, 32, 52.	2.2	0
802	Targeted therapy for liver cancer: updated review in 2012. Current Cancer Drug Targets, 2012, 12, 1062-72.	1.6	24
803	Tailor-Made Therapy for Viral Hepatitis: Recent Advances. Digestion, 2011, 84, 1-4.	2.3	2
804	Preface. Pancreatology, 2011, 11, 1-2.	1.1	0
805	P38alpha Inhibits Liver Fibrogenesis and Consequent Hepatocarcinogenesis by Curtailing Accumulation of Reactive Oxygen Species. Gastroenterology, 2011, 140, S-927.	1.3	0
806	Endoscopic Ultrasonography-Guided Biliary Drainage: Evaluation of a Choledochoduodenostomy Technique. Pancreatology, 2011, 11, 47-51.	1.1	48
807	Endoscopic Ultrasonography and Contrast-Enhanced Endoscopic Ultrasonography. Pancreatology, 2011, 11, 28-33.	1.1	34
808	Involvement of Angiotensin II and Reactive Oxygen Species in Pancreatic Fibrosis. Pancreatology, 2011, 11, 7-13.	1.1	30
809	The Usefulness of Helicobacter pylori Eradication Therapy for the Healing of Artificial Gastric Ulcer After Endoscopic Submucosal Dissection for Early Gastric Cancer. Gastroenterology, 2011, 140, S-312.	1.3	1
810	Estimation of malignant potential of GI stromal tumors by contrast-enhanced harmonic EUS (with) Tj ETQq0 0 0 rgBTj/Overlock 10 Tf 50	1.0	98

#	ARTICLE	IF	CITATIONS
811	mTOR Inhibitor for the Treatment of Hepatocellular Carcinoma. Digestive Diseases, 2011, 29, 310-315.	1.9	20
812	Hepatocellular Carcinoma in 2011 and Beyond: From the Pathogenesis to Molecular Targeted Therapy. Oncology, 2011, 81, 1-10.	1.9	23
813	Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version. Digestive Diseases, 2011, 29, 339-364.	1.9	726
814	Prevention of Delayed Bleeding After Endoscopic Submucosal Dissection (ESD) for Gastric Tumors. Gastroenterology, 2011, 140, S-235.	1.3	3
815	Endoscopic Ultrasound-Guided Neurolysis in Pancreatic Cancer. Pancreatology, 2011, 11, 52-58.	1.1	33
816	Association of Interleukin-28B and Hepatitis C Genotype 1 with a High Viral Load and Response to Pegylated Interferon plus Ribavirin Therapy. Digestion, 2011, 84, 56-61.	2.3	5
817	Assessment of Hepatobiliary Phase Gd-EOB-DTPA-Enhanced MRI for HCC and Borderline Lesions and Comparison of Detection Ability Versus MDCT. Gastroenterology, 2011, 140, S-920.	1.3	0
818	Peginterferon ALPHA-2A (40KD) Plus Ribavirin for the Treatment of Patients With Chronic Hepatitis C (CHC) and Compensated Liver Cirrhosis in Japan. Gastroenterology, 2011, 140, S-950.	1.3	0
819	Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. European Journal of Cancer, 2011, 47, 2117-2127.	2.8	496
820	Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009. Hepatology Research, 2011, 41, 1-21.	3.4	24
821	Demonstration of quality of care measurement using the Japanese liver cancer registry. Hepatology Research, 2011, 41, 1208-1215.	3.4	17
822	Estimation of Liver Function Using T1 Mapping on Gd-EOB-DTPA-Enhanced Magnetic Resonance Imaging. Investigative Radiology, 2011, 46, 277-283.	6.2	178
823	NEW TECHNIQUES AND FUTURE PERSPECTIVE OF EUS FOR THE DIFFERENTIAL DIAGNOSIS OF PANCREATIC MALIGNANCIES: CONTRAST HARMONIC IMAGING. Digestive Endoscopy, 2011, 23, 46-50.	2.3	50
824	Correlation between hyporesponsiveness to Toll-like receptor ligands and liver dysfunction in patients with chronic hepatitis C virus infection. Journal of Viral Hepatitis, 2011, 18, e561-e567.	2.0	18
825	Signaling Pathways Governing Tumor Angiogenesis. Oncology, 2011, 81, 24-29.	1.9	159
826	The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon $\hat{1}\pm$ -2b therapy against advanced hepatocellular carcinoma. Journal of Gastroenterology, 2011, 46, 212-221.	5.1	14
827	Phenotype-dependent production of des- $\hat{1}\pm$ -carboxy prothrombin in hepatocellular carcinoma. Journal of Gastroenterology, 2011, 46, 1219-1229.	5.1	9
828	Identifying and prioritizing strategies for comprehensive liver cancer control in Asia. BMC Health Services Research, 2011, 11, 298.	2.2	17

#	ARTICLE	IF	CITATIONS
829	Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma. <i>Liver Transplantation</i> , 2011, 17, S67-S71.	2.4	20
830	Optimal scanning protocol of arterial dominant phase for hypervascular hepatocellular carcinoma with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced MR. <i>Journal of Magnetic Resonance Imaging</i> , 2011, 33, 864-872.	3.4	19
831	Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. <i>Hepatology</i> , 2011, 54, 532-540.	7.3	100
832	Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2011, 98, 552-557.	0.3	83
833	Diagnostic Imaging of Hepatocellular Carcinoma: Recent Progress. <i>Oncology</i> , 2011, 81, 73-85.	1.9	57
834	Adjuvant Therapy after Curative Treatment for Hepatocellular Carcinoma. <i>Oncology</i> , 2011, 81, 50-55.	1.9	43
835	Sorafenib Inhibits the Hepatocyte Growth Factor-Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 169-177.	4.1	109
836	Antitumor Activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2+pTyr+ Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker <i>In Vivo</i> . <i>Clinical Cancer Research</i> , 2011, 17, 1373-1381.	7.0	34
837	Oral Branched-Chain Amino Acid Granules Reduce the Incidence of Hepatocellular Carcinoma and Improve Event-Free Survival in Patients with Liver Cirrhosis. <i>Digestive Diseases</i> , 2011, 29, 326-332.	1.9	57
838	Correlation between Insulin Resistance and Outcome of Pegylated Interferon and Ribavirin Therapy, Hepatic Steatosis, Hepatic Fibrosis in Chronic Hepatitis C-1b and High Viral Load. <i>Digestion</i> , 2011, 84, 5-9.	2.3	2
839	Radiofrequency Ablation of Hepatocellular Carcinoma: A Literature Review. <i>International Journal of Hepatology</i> , 2011, 2011, 1-9.	1.1	73
840	Double-Filtration Plasmapheresis plus Interferon- β for HCV-1b Patients with Non-Sustained Virological Response to Previous Combination Therapy. <i>Digestion</i> , 2011, 84, 10-16.	2.3	4
841	Clinical Characteristics of Non-B Non-C Hepatocellular Carcinoma: A Single-Center Retrospective Study. <i>Digestion</i> , 2011, 84, 43-49.	2.3	22
842	Signaling Pathway and Molecular-Targeted Therapy for Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2011, 29, 289-302.	1.9	33
843	Future Treatment Option for Hepatocellular Carcinoma: A Focus on Brivanib. <i>Digestive Diseases</i> , 2011, 29, 316-320.	1.9	9
844	Des- β -Carboxyprothrombin May Be a Promising Biomarker to Determine the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2011, 29, 321-325.	1.9	49
845	Complete Response of Advanced Hepatocellular Carcinoma with Multiple Lung Metastases Treated with Sorafenib: A Case Report. <i>Oncology</i> , 2011, 81, 152-157.	1.9	41
846	Adriamycin Enhances Proteasome-Mediated Generation of the Proapoptotic Processed Form of MAGE-A4 in Hepatoma Cells. <i>Oncology</i> , 2011, 81, 30-35.	1.9	12

#	ARTICLE	IF	CITATIONS
847	Molecular Targeted Therapy for Hepatocellular Carcinoma: Bench to Bedside. Digestive Diseases, 2011, 29, 273-277.	1.9	19
848	Double-Contrast Ultrasound: A Novel Surveillance Tool for Hepatocellular Carcinoma. American Journal of Gastroenterology, 2011, 106, 368-370.	0.4	51
849	Usefulness of Combination of Imaging Modalities in the Diagnosis of Hepatocellular Carcinoma Using Sonazoid®-Enhanced Ultrasound, Gadolinium Diethylene-Triamine-Pentaacetic Acid-Enhanced Magnetic Resonance Imaging, and Contrast-Enhanced Computed Tomography. Oncology, 2011, 81, 66-72.	1.9	36
850	Recent Advances in the Management of Chronic Hepatitis B. Hepatitis Monthly, 2011, 11, 601-11.	0.2	8
851	The status of polycystic liver disease in Japan: a questionnaire survey of patients. Acta Hepatologica Japonica, 2011, 52, 709-715.	0.1	2
852	Review of dynamic contrast-enhanced ultrasound guidance in ablation therapy for hepatocellular carcinoma. World Journal of Gastroenterology, 2011, 17, 4952.	3.3	55
853	Endoscopic Characteristics of Colorectal Serrated Lesions. Hepato-Gastroenterology, 2011, 58, 1189-1192.	0.5	22
854	Proposed treatment guidance on new anticancer agents for the treatment of hepatocellular carcinoma, 2010 up date. Acta Hepatologica Japonica, 2011, 52, 532-551.	0.1	0
855	Abstract 3371: Expression levels of EMT-related genes in hepatocellular carcinoma. , 2011, , .		0
856	Abstract 4185: Serum concentrations of angiogenesis-related molecules in patients with pancreatic cancer. , 2011, , .		0
857	Cecal Intussusception in an Adult with Cronkhite-Canada Syndrome Relieved by Colonoscopy. Internal Medicine, 2010, 49, 1123-1126.	0.7	9
858	Autoimmune Thrombocytopenic Purpura during Pegylated Interferon .ALPHA. Treatment for Chronic Hepatitis C. Internal Medicine, 2010, 49, 1119-1122.	0.7	6
859	JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis B. Acta Hepatologica Japonica, 2010, 51, 243-260.	0.1	0
860	Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice. International Journal of Clinical Oncology, 2010, 15, 242-255.	2.2	30
861	Single HCC between 2 and 5 cm: the grey zone. Journal of Hepato-Biliary-Pancreatic Sciences, 2010, 17, 434-437.	2.6	3
862	Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatology International, 2010, 4, 439-474.	4.2	944
863	A novel biomarker TERTmRNA is applicable for early detection of hepatoma. BMC Gastroenterology, 2010, 10, 46.	2.0	32
864	Identification and characterization of IgG4-associated autoimmune hepatitis. Liver International, 2010, 30, 222-231.	3.9	89

#	ARTICLE	IF	CITATIONS
865	Age and immunoglobulin G4-associated autoimmune hepatitis: author's response. Liver International, 2010, 30, 333-333.	3.9	0
866	Radiofrequency ablation guided by contrast harmonic sonography using perfluorocarbon microbubbles (Sonazoid) for hepatic malignancies: an initial experience. Liver International, 2010, 30, 759-764.	3.9	48
867	Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafenib (GIDEON) study. International Journal of Clinical Practice, 2010, 64, 1034-1041.	1.7	66
868	Phase I/II study of the pharmacokinetics, safety and efficacy of Sâ€1 in patients with advanced hepatocellular carcinoma. Cancer Science, 2010, 101, 2606-2611.	3.9	28
869	The 2008 Okuda lecture: Management of hepatocellular carcinoma: From surveillance to molecular targeted therapy. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 439-452.	2.8	98
870	PANCREATIC DUCTAL DRAINAGE BY ENDOSCOPIC ULTRASOUNDâ€ASSISTED RENDEZVOUS TECHNIQUE FOR PAIN CAUSED BY DUCTAL STRICTURE WITH CHRONIC PANCREATITIS. Digestive Endoscopy, 2010, 22, 217-219.	2.3	11
871	Response Evaluation Criteria in Cancer of the Liver (RECICL). Acta Hepatologica Japonica, 2010, 51, 261-266.	0.1	20
872	Non-invasive evaluation method of the liver fibrosis using Real-time Tissue Elastography âˆ¼Usefulness of judgment liver fibrosis stage by Liver Fibrosis Index (LF index). Acta Hepatologica Japonica, 2010, 51, 539-541.	0.1	20
873	Diagnosis of pancreatic tumors by endoscopic ultrasonography. World Journal of Radiology, 2010, 2, 122.	1.1	30
874	Hepatic malignancies: Correlation between sonographic findings and pathological features. World Journal of Radiology, 2010, 2, 249.	1.1	38
875	The Challenge of Prognosis and Staging for Hepatocellular Carcinoma. Oncologist, 2010, 15, 23-33.	3.7	121
876	Real Practice of Hepatocellular Carcinoma in Japan: Conclusions of the Japan Society of Hepatology 2009 Kobe Congress. Oncology, 2010, 78, 180-188.	1.9	46
877	Viral Hepatitis A to E: An Update in 2010. Intervirology, 2010, 53, 5-9.	2.8	0
878	Double-Filtration Plasmapheresis plus IFN for HCV-1b Patients with Non-Sustained Virological Response to Previous Combination Therapy: Early Viral Dynamics. Intervirology, 2010, 53, 44-48.	2.8	4
879	Outcome and Early Viral Dynamics with Viral Mutation in PEG-IFN/RBV Therapy for Chronic Hepatitis in Patients with High Viral Loads of Serum HCV RNA Genotype 1b. Intervirology, 2010, 53, 49-54.	2.8	8
880	PEG-IFNâˆ¼/RBV Combination Therapy for Chronic Hepatitis C Patients Increases Serum Ferritin Level while It Improves Sustained Viral Response Rate. Intervirology, 2010, 53, 60-65.	2.8	5
881	Non-Invasive Evaluation of Hepatic Fibrosis for Type C Chronic Hepatitis. Intervirology, 2010, 53, 76-81.	2.8	71
882	Liver Cancer Working Group Report. Japanese Journal of Clinical Oncology, 2010, 40, i19-i27.	1.3	65

#	ARTICLE	IF	CITATIONS
883	Changing Trends in Hepatitis C Infection over the Past 50 Years in Japan. Intervirology, 2010, 53, 39-43.	2.8	147
884	Prolonged PEG-IFN and RBV Is Effective in Patients with HCV Genotype 1 and High Viral Load Who Achieved Virological Response Later than 24 Weeks. Intervirology, 2010, 53, 55-59.	2.8	3
885	EUS-Guided Broad Plexus Neurolysis Over the Superior Mesenteric Artery Using a 25-Gauge Needle. American Journal of Gastroenterology, 2010, 105, 2599-2606.	0.4	83
886	Endoscopic ultrasound (EUS)-guided transluminal endoscopic removal of gallstones. Endoscopy, 2010, 42, E331-E332.	1.8	9
887	Hepatitis C Virus Core Protein Induces Homotolerance and Cross-Tolerance to Toll-Like Receptor Ligands by Activation of Toll-Like Receptor 2. Journal of Infectious Diseases, 2010, 202, 853-861.	4.0	47
888	Endoscopic findings of intestinal Behçet's disease complicated with toxic megacolon. Endoscopy, 2010, 42, E173-E174.	1.8	5
889	Management of Hepatocellular Carcinoma: From Prevention to Molecular Targeted Therapy. Oncology, 2010, 78, 1-6.	1.9	17
890	Newly Developed Novel Ultrasound Technique, Defect Reperfusion Ultrasound Imaging, Using Sonazoid in the Management of Hepatocellular Carcinoma. Oncology, 2010, 78, 40-45.	1.9	93
891	Usefulness of the Post-Vascular Phase of Contrast-Enhanced Ultrasonography with Sonazoid in the Evaluation of Gross Types of Hepatocellular Carcinoma. Oncology, 2010, 78, 53-59.	1.9	30
892	Depiction of Portal Supply in Early Hepatocellular Carcinoma and Dysplastic Nodule: Value of Pure Arterial Ultrasound Imaging in Hepatocellular Carcinoma. Oncology, 2010, 78, 60-67.	1.9	28
893	Contrast-Enhanced Ultrasound Techniques for Guiding and Assessing Response to Locoregional Treatments for Hepatocellular Carcinoma. Oncology, 2010, 78, 68-77.	1.9	11
894	Will Gd-EOB-MRI Change the Diagnostic Algorithm in Hepatocellular Carcinoma?. Oncology, 2010, 78, 87-93.	1.9	70
895	Radiofrequency Ablation for Hepatocellular Carcinoma: Assistant Techniques for Difficult Cases. Oncology, 2010, 78, 94-101.	1.9	29
896	Radiofrequency Ablation for Hepatocellular Carcinoma: Updated Review in 2010. Oncology, 2010, 78, 113-124.	1.9	134
897	Hepatic Arterial Infusion Chemotherapy Using Low-Dose 5-Fluorouracil and Cisplatin for Advanced Hepatocellular Carcinoma. Oncology, 2010, 78, 148-153.	1.9	87
898	Positioning of a Molecular-Targeted Agent, Sorafenib, in the Treatment Algorithm for Hepatocellular Carcinoma and Implication of Many Complete Remission Cases in Japan. Oncology, 2010, 78, 154-166.	1.9	89
899	Overall Survival After Transarterial Lipiodol Infusion Chemotherapy With or Without Embolization for Unresectable Hepatocellular Carcinoma: Propensity Score Analysis. American Journal of Roentgenology, 2010, 194, 830-837.	2.2	102
900	EUS-guided in vivo microdialysis of the pancreas: a novel technique with potential diagnostic and therapeutic application. Gastrointestinal Endoscopy, 2010, 71, 176-179.	1.0	6

#	ARTICLE	IF	CITATIONS
901	T1436: EUS-Guided Gallbladder Drainage for Treatment of Acute Cholecystitis and Obstructive Jaundice. <i>Gastrointestinal Endoscopy</i> , 2010, 71, AB276-AB277.	1.0	1
902	T1437: EUS-Guided Choledochoduodenostomy Followed by Endoscopic Antegrade Biliary Stenting via the Fistula for Treatment of Obstructive Jaundice With Duodenal Stenosis. <i>Gastrointestinal Endoscopy</i> , 2010, 71, AB277.	1.0	0
903	Characterization of intra-abdominal lesions of undetermined origin by contrast-enhanced harmonic EUS (with videos). <i>Gastrointestinal Endoscopy</i> , 2010, 72, 637-642.	1.0	47
904	Report of the 18th follow-up survey of primary liver cancer in Japan. <i>Hepatology Research</i> , 2010, 40, 1043-1059.	3.4	120
905	Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009). <i>Hepatology Research</i> , 2010, 40, 347-368.	3.4	40
906	Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). <i>Hepatology Research</i> , 2010, 40, 667-685.	3.4	154
907	Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version). <i>Hepatology Research</i> , 2010, 40, 686-692.	3.4	130
908	PIVKA-II is a predictive marker in the treatment response of sorafenib to hepatocellular carcinoma. <i>Acta Hepatologica Japonica</i> , 2010, 51, 681-683.	0.1	6
909	Diagnostic sensitivity of imaging modalities for hepatocellular carcinoma smaller than 2 cm. <i>World Journal of Gastroenterology</i> , 2010, 16, 4187.	3.3	64
910	Radiofrequency ablation of hepatocellular carcinoma: Current status. <i>World Journal of Radiology</i> , 2010, 2, 417.	1.1	85
911	Diagnosis of subepithelial tumors in the upper gastrointestinal tract by endoscopic ultrasonography. <i>World Journal of Radiology</i> , 2010, 2, 289.	1.1	54
912	Elevated serum ALT levels following hyperferritinemia in CHC patients receiving pegylated interferon (PEG-IFN) therapy and availability of phlebotomy. <i>Acta Hepatologica Japonica</i> , 2010, 51, 371-378.	0.1	0
913	JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis C. <i>Acta Hepatologica Japonica</i> , 2009, 50, 665-677.	0.1	0
914	Utility of Gd-EOB-DTPA-Enhanced MRI in Diagnosing Small Hepatocellular Carcinoma. <i>Case Reports in Gastroenterology</i> , 2009, 3, 187-192.	0.6	1
915	Percutaneous Aspiration and Ethanolamine Oleate Sclerotherapy for Sustained Resolution of Symptomatic Polycystic Liver Disease: An Initial Experience. <i>American Journal of Roentgenology</i> , 2009, 193, 1540-1545.	2.2	43
916	Value of Liver Parenchymal Phase Contrast-Enhanced Sonography to Diagnose Premalignant and Borderline Lesions and Overt Hepatocellular Carcinoma. <i>American Journal of Roentgenology</i> , 2009, 192, 698-705.	2.2	28
917	Extramullary plasmacytoma of the colon: a rare cause of gastrointestinal bleeding. <i>Endoscopy</i> , 2009, 41, E306-E307.	1.8	9
918	Crohn's Disease with Gastroduodenal Mucosa Lesions that Are Similar to the Lesions Caused by Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 646-648.	1.9	0

#	ARTICLE	IF	CITATIONS
919	Campylobacter fetus Meningitis in a Patient with Crohn's Disease. Inflammatory Bowel Diseases, 2009, 15, 645-646.	1.9	11
920	Multistep human hepatocarcinogenesis: correlation of imaging with pathology. Journal of Gastroenterology, 2009, 44, 112-118.	5.1	197
921	Small cell carcinoma of the pancreas: role of EUS-FNA and subsequent effective chemotherapy using carboplatin and etoposide. Journal of Gastroenterology, 2009, 44, 432-438.	5.1	16
922	Well-differentiated hepatocellular carcinoma smaller than 15Âmm in diameter totally eradicated with percutaneous ethanol injection instead of radiofrequency ablation. Hepatology International, 2009, 3, 411-415.	4.2	11
923	Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients. Journal of Viral Hepatitis, 2009, 16, 388-396.	2.0	22
924	Prospective comparative study of the EUS guided 25â€gauge FNA needle with the 19â€gauge Trucut needle and 22â€gauge FNA needle in patients with solid pancreatic masses. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 384-390.	2.8	213
925	PRESENT STATUS AND FUTURE PERSPECTIVE OF EUS-GUIDED DRAINAGE. Digestive Endoscopy, 2009, 21, S66-70.	2.3	10
926	Consensus report of the 2nd International Forum for Liver MRI. European Radiology, 2009, 19, 975-989.	4.5	125
927	Pegylated Interferon plus Ribavirin Combination Therapy for Chronic Hepatitis C with High Viral Load of Serum Hepatitis C Virus RNA, Genotype 1b, Discontinued on Attaining Sustained Virological Response at Week 16 after Onset of Acute Pancreatitis. Digestion, 2009, 79, 36-39.	2.3	5
928	Hepatectomy versus radiofrequency ablation for early hepatocellular carcinoma: Reply. Journal of Hepatology, 2009, 50, 1052-1053.	3.7	10
929	Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: A randomized phase III trial. Journal of Hepatology, 2009, 51, 1030-1036.	3.7	90
930	Dynamic imaging of pancreatic tumors by contrast-enhanced harmonic EUS with long-lasting contrast. Gastrointestinal Endoscopy, 2009, 69, S228.	1.0	2
931	EUS-Guided In Vivo Microdialysis of Pancreas: A Novel Technique of Potential Diagnostic and Therapeutic Application. Gastrointestinal Endoscopy, 2009, 69, AB138.	1.0	0
932	Dynamic Imaging By Contrast-Enhanced Harmonic EUS with Long-Lasting Contrast: Role in Diagnosis of Pancreatic Tumors. Gastrointestinal Endoscopy, 2009, 69, AB235-AB236.	1.0	4
933	Contrast-Enhanced Harmonic EUS of Intra-Abdominal Lesions with Undetermined Origin: Initial Observation of Vascularity Depiction. Gastrointestinal Endoscopy, 2009, 69, AB327.	1.0	0
934	FNA Guided By Contrast-Enhanced Harmonic EUS in Pancreatic Tumors. Gastrointestinal Endoscopy, 2009, 69, AB328-AB329.	1.0	7
935	JSH Consensus Kobe 2009; Diagnosis and Treatment of NASH. Acta Hepatologica Japonica, 2009, 50, 741-747.	0.1	10
936	Scirrhus hepatocellular carcinoma displaying atypical findings on imaging studies. World Journal of Gastroenterology, 2009, 15, 2296.	3.3	9

#	ARTICLE	IF	CITATIONS
937	Small invasive ductal carcinoma of the pancreas distinct from branch duct intraductal papillary mucinous neoplasm. <i>World Journal of Gastroenterology</i> , 2009, 15, 5489.	3.3	21
938	Contrast-enhanced harmonic ultrasound imaging in ablation therapy for primary hepatocellular carcinoma. <i>World Journal of Radiology</i> , 2009, 1, 86.	1.1	13
939	Panel discussion: Management of hepatocellular carcinoma. <i>Acta Hepatologica Japonica</i> , 2009, 50, 407-426.	0.1	0
940	Comparison of an ecabet sodium and proton pump inhibitor (PPI) combination therapy with PPI alone in the treatment of endoscopic submucosal dissection (ESD)-induced ulcers in early gastric cancer: prospective randomized study. <i>Hepato-Gastroenterology</i> , 2009, 56, 1270-3.	0.5	14
941	Effects of decorin on the expression of α -smooth muscle actin in a human myofibroblast cell line. <i>Molecular and Cellular Biochemistry</i> , 2008, 308, 201-207.	3.1	15
942	Preliminary study of contrast-enhanced harmonic endosonography with second-generation contrast agents. <i>Journal of Medical Ultrasonics</i> (2001), 2008, 35, 11-18.	1.3	36
943	Utility of Contrast-Enhanced Endoscopic Ultrasonography for Diagnosis of Small Pancreatic Carcinomas. <i>Ultrasound in Medicine and Biology</i> , 2008, 34, 525-532.	1.5	162
944	Foreign body granuloma mimicking disseminated tumour recurrence after radiofrequency ablation for hepatocellular carcinoma. <i>Liver International</i> , 2008, 28, 414-415.	3.9	3
945	Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score. <i>Journal of Gastroenterology and Hepatology</i> (Australia), 2008, 23, 445-452.	2.8	47
946	Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. <i>Surgery</i> , 2008, 143, 469-475.	1.9	341
947	Differential Diagnosis of Hepatic Tumors: Value of Contrast-Enhanced Harmonic Sonography Using the Newly Developed Contrast Agent, Sonazoid. <i>Intervirolgy</i> , 2008, 51, 61-69.	2.8	139
948	A novel perfusion imaging technique of the pancreas: contrast-enhanced harmonic EUS (with video). <i>Gastrointestinal Endoscopy</i> , 2008, 67, 141-150.	1.0	198
949	Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. <i>Journal of Hepatology</i> , 2008, 49, 223-232.	3.7	90
950	Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: A preliminary report of the Japanese nationwide survey. <i>Journal of Hepatology</i> , 2008, 49, 589-594.	3.7	160
951	Molecular mechanisms of portal vein tolerance. <i>Hepatology Research</i> , 2008, 38, 441-449.	3.4	10
952	Erratum. <i>Hepatology Research</i> , 2008, 38, 638-638.	3.4	1
953	Sonazoid-enhanced Ultrasound in the Diagnosis and Treatment of Hepatic Tumors. <i>Journal of Medical Ultrasound</i> , 2008, 16, 130-139.	0.4	42
954	Defect Reperfusion Imaging, a Newly Developed Novel Technology using Sonazoid in the Treatment of Hepatocellular Carcinoma. <i>Journal of Medical Ultrasound</i> , 2008, 16, 169-176.	0.4	34

#	ARTICLE	IF	CITATIONS
955	Noninvasive Evaluation of Hepatic Fibrosis Using Serum Fibrotic Markers, Transient Elastography (FibroScan) and Real-Time Tissue Elastography. <i>Intervirolgy</i> , 2008, 51, 27-33.	2.8	94
956	Usefulness of a New Immunoradiometric Assay of HCV Core Antigen to Predict Virological Response during PEG-IFN/RBV Combination Therapy for Chronic Hepatitis with High Viral Load of Serum HCV RNA Genotype 1b. <i>Intervirolgy</i> , 2008, 51, 70-75.	2.8	46
957	Elevated Serum ALT Levels during Pegylated Interferon Monotherapy May Be Caused by Hepatic Iron Overload. <i>Intervirolgy</i> , 2008, 51, 76-85.	2.8	11
958	Diagnostic Accuracy of Imaging for Liver Cirrhosis Compared to Histologically Proven Liver Cirrhosis. <i>Intervirolgy</i> , 2008, 51, 17-26.	2.8	128
959	A New Prognostic Staging System for Hepatocellular Carcinoma: Value of the Biomarker Combined Japan Integrated Staging Score. <i>Intervirolgy</i> , 2008, 51, 86-94.	2.8	41
960	Epidemiology of Hepatocellular Carcinoma in Japan and Korea. <i>Oncology</i> , 2008, 75, 13-16.	1.9	57
961	Impact of Interferon Therapy after Curative Treatment of Hepatocellular Carcinoma. <i>Oncology</i> , 2008, 75, 30-41.	1.9	22
962	Sonazoid-Enhanced Ultrasonography for Diagnosis of Hepatic Malignancies: Comparison with Contrast-Enhanced CT. <i>Oncology</i> , 2008, 75, 42-47.	1.9	115
963	Imaging of Hepatocellular Carcinoma: Qualitative and Quantitative Analysis of Postvascular Phase Contrast-Enhanced Ultrasonography with Sonazoid. <i>Oncology</i> , 2008, 75, 48-54.	1.9	39
964	Intranodular Blood Supply Correlates Well with Biological Malignancy Grade Determined by Tumor Growth Rate in Pathologically Proven Hepatocellular Carcinoma. <i>Oncology</i> , 2008, 75, 55-64.	1.9	21
965	Validation of a New Prognostic Staging System for Hepatocellular Carcinoma: A Comparison of the Biomarker-Combined Japan Integrated Staging Score, the Conventional Japan Integrated Staging Score and the BALAD Score. <i>Oncology</i> , 2008, 75, 83-90.	1.9	64
966	PIVKA-II Is the Best Prognostic Predictor in Patients with Hepatocellular Carcinoma after Radiofrequency Ablation Therapy. <i>Oncology</i> , 2008, 75, 91-98.	1.9	23
967	Response Evaluation of Transcatheter Arterial Chemoembolization in Hepatocellular Carcinomas: The Usefulness of Sonazoid-Enhanced Harmonic Sonography. <i>Oncology</i> , 2008, 75, 99-105.	1.9	63
968	Combination Therapy with S-1 and Pegylated Interferon Alpha for Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2008, 75, 106-113.	1.9	18
969	Long-Term Follow-Up of Atypical Progressive Focal Nodular Hyperplasia Increasing in Size and Number Implicates Its Pathogenesis. <i>American Journal of Gastroenterology</i> , 2008, 103, 2153-2155.	0.4	7
970	In situ carcinoma of pancreas diagnosed by EUS-FNA. <i>Endoscopy</i> , 2008, 40, E15-E16.	1.8	6
971	Hepatocellular Carcinoma 2009 and Beyond: from the Surveillance to Molecular Targeted Therapy. <i>Oncology</i> , 2008, 75, 1-12.	1.9	108
972	Radiofrequency Ablation of Hepatocellular Carcinoma: Value of Virtual CT Sonography with Magnetic Navigation. <i>American Journal of Roentgenology</i> , 2008, 190, W335-W341.	2.2	106

#	ARTICLE	IF	CITATIONS
973	Intracystic Hemorrhage in a Patient of Polycystic Kidney with Renocolic Fistula Diagnosed by Contrast-Enhanced Ultrasonography. <i>Internal Medicine</i> , 2008, 47, 1977-1979.	0.7	4
974	Focal Nodular Hyperplasia-like Lesion with Venous Washout in Alcoholic Liver Cirrhosis. <i>Internal Medicine</i> , 2008, 47, 1899-1903.	0.7	14
975	Long-term outcome of percutaneous ethanol injection therapy for minimum-sized hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2008, 14, 1997.	3.3	27
976	Endoscopic findings can predict the efficacy of leukocytapheresis for steroid-naïve patients with moderately active ulcerative colitis. <i>World Journal of Gastroenterology</i> , 2008, 14, 5316.	3.3	5
977	Pegylated interferon α -2b/ribavirin combination therapy for elderly patients with chronic hepatitis C with high viral load of HCV genotype 1b. <i>Acta Hepatologica Japonica</i> , 2008, 49, 145-152.	0.1	0
978	The clinical characteristics, endoscopic treatment, and prognosis for patients presenting with duodenal varices. <i>Hepato-Gastroenterology</i> , 2008, 55, 959-62.	0.5	9
979	Multistep progression from a hypovascular nodule to a nodule-in-nodule type hepatocellular carcinoma in hepatitis C-related cirrhosis. <i>Indian Journal of Gastroenterology</i> , 2008, 27, 176.	1.4	2
980	Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Manual Proposed by the Japan Society of Hepatology. <i>Oncology</i> , 2007, 72, 2-15.	1.9	172
981	Severe Complications of Radiofrequency Ablation Therapy for Hepatocellular Carcinoma: An Analysis of 3,891 Ablations in 2,614 Patients. <i>Oncology</i> , 2007, 72, 72-75.	1.9	100
982	Outcomes of Nontransplant Potentially Curative Therapy for Early-Stage Hepatocellular Carcinoma in Child-Pugh Stage A Cirrhosis Is Comparable with Liver Transplantation. <i>Digestive Diseases</i> , 2007, 25, 303-309.	1.9	31
983	Superiority of CT Arteriportal Angiography to Contrast-Enhanced CT and MRI in the Diagnosis of Hepatocellular Carcinoma in Nodules Smaller than 2 cm. <i>Oncology</i> , 2007, 72, 58-66.	1.9	17
984	What Is the Best Time to Evaluate Treatment Response after Radiofrequency Ablation of Hepatocellular Carcinoma Using Contrast-Enhanced Sonography?. <i>Oncology</i> , 2007, 72, 92-97.	1.9	19
985	Initial Treatment Response Is Essential to Improve Survival in Patients with Hepatocellular Carcinoma Who Underwent Curative Radiofrequency Ablation Therapy. <i>Oncology</i> , 2007, 72, 98-103.	1.9	88
986	Natural Course of Small Nodular Lesions with Intranodular Preserved Portal Supply in Cirrhotic Liver. <i>Oncology</i> , 2007, 72, 24-29.	1.9	7
987	Long-Term Interferon Maintenance Therapy Improves Survival in Patients with HCV-Related Hepatocellular Carcinoma after Curative Radiofrequency Ablation. <i>Oncology</i> , 2007, 72, 132-138.	1.9	64
988	Contrast Harmonic Sonography-Guided Radiofrequency Ablation Therapy Versus B-Mode Sonography in Hepatocellular Carcinoma: Prospective Randomized Controlled Trial. <i>American Journal of Roentgenology</i> , 2007, 188, 489-494.	2.2	85
989	Percutaneous Radiofrequency Ablation of Sonographically Unidentifiable Liver Tumors. <i>Oncology</i> , 2007, 72, 111-116.	1.9	46
990	Development of a Novel Assay to Quantify Serum Human Telomerase Reverse Transcriptase Messenger RNA and Its Significance as a Tumor Marker for Hepatocellular Carcinoma. <i>Oncology</i> , 2007, 72, 45-51.	1.9	29

#	ARTICLE	IF	CITATIONS
991	Endoscopic ultrasound-guided pancreaticogastrostomy reconstruction. <i>Endoscopy</i> , 2007, 39, E70-E71.	1.8	6
992	Clinical Characteristics of NonBNonC- HCC: Comparison with HBV and HCV Related HCC. <i>Intervirolgy</i> , 2007, 50, 24-31.	2.8	44
993	Antibody to Hepatitis B Core Antigen and Risk for Hepatitis Câ€‘Related Hepatocellular Carcinoma. <i>Annals of Internal Medicine</i> , 2007, 146, 649.	3.9	130
994	Report of the 17th Nationwide Followâ€‘up Survey of Primary Liver Cancer in Japanâ€‘. <i>Hepatology Research</i> , 2007, 37, 676-691.	3.4	376
995	Small hepatocellular carcinoma presenting with massive metastasis in the peritoneum, mimicking sarcomatous tumor. <i>Hepatology Research</i> , 2007, 37, 885-889.	3.4	5
996	First Attempt of Boron Neutron Capture Therapy (BNCT) for Hepatocellular Carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2007, 37, 376-381.	1.3	87
997	Clinical Application of Contrast-Enhanced Harmonic Imaging toâ€‘Endosonography. <i>Gastrointestinal Endoscopy</i> , 2007, 65, AB193.	1.0	0
998	A proposal of novel treatment-assist technique for hepatocellular carcinoma in the Sonazoid-enhanced ultrasonography: value of defect re-perfusion imaging. <i>Acta Hepatologica Japonica</i> , 2007, 48, 299-301.	0.1	26
999	Diagnosis of Gallbladder Diseases by Contrast-Enhanced Phase-Inversion Harmonic Ultrasonography. <i>Ultrasound in Medicine and Biology</i> , 2007, 33, 353-361.	1.5	58
1000	MIXED INTESTINAL- AND DIFFUSE-TYPE HISTOLOGY IS A RISK FACTOR FOR LYMPH NODE METASTASIS OF SUBMUCOSAL INVASIVE GASTRIC CANCER. <i>Digestive Endoscopy</i> , 2007, 20, 17-21.	2.3	1
1001	Case of rapidly progressed sarcomatoid hepatocellular carcinoma in a young female without risk factor. <i>Liver International</i> , 2007, 27, 1428-1430.	3.9	5
1002	Review of 4th Single Topic Conference on HCC. <i>Hepatology Research</i> , 2007, 37, S83-7.	3.4	8
1003	Role of tumor markers in assessment of tumor progression and prediction of outcomes in patients with hepatocellular carcinoma. <i>Hepatology Research</i> , 2007, 37, S166-71.	3.4	28
1004	New sonographic techniques for the diagnosis and treatment of hepatocellular carcinoma. <i>Hepatology Research</i> , 2007, 37, S193-9.	3.4	48
1005	Review of current staging systems for hepatocellular carcinoma. <i>Hepatology Research</i> , 2007, 37, S210-5.	3.4	7
1006	International comparison of treatment outcomes based on staging systems. <i>Hepatology Research</i> , 2007, 37, S216-S222.	3.4	4
1007	Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2007, 41, 1214-1219.	5.1	53
1008	Well to moderately differentiated HCC manifesting hyperattenuation on both CT during arteriography and arterial portography. <i>World Journal of Gastroenterology</i> , 2007, 13, 5775.	3.3	6

#	ARTICLE	IF	CITATIONS
1009	Multistep hepatocarcinogenesis from a dysplastic nodule to well-differentiated hepatocellular carcinoma in a patient with alcohol-related liver cirrhosis. <i>World Journal of Gastroenterology</i> , 2007, 13, 1271.	3.3	11
1010	Dissemination of clinical practice guidelines for hepatocellular carcinoma among Japanese hepatologists and liver surgeons. <i>Acta Hepatologica Japonica</i> , 2007, 48, 562-570.	0.1	0
1011	Treatment of large and/or multiple hepatic malignancies: open surgical approaches of radiofrequency ablation. <i>Hepato-Gastroenterology</i> , 2007, 54, 2358-60.	0.5	6
1012	Staging Hepatocellular Carcinoma by a Novel Scoring System (BALAD Score) Based on Serum Markers. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1528-1536.	4.4	97
1013	Cecal Necrosis Due to Ischemic Colitis Mimicking an Abscess on Sonography. <i>Journal of Ultrasound in Medicine</i> , 2006, 25, 393-396.	1.7	5
1014	WEGENER'S GRANULOMATOSIS COMPLICATED WITH APHTHOID COLITIS. <i>Digestive Endoscopy</i> , 2006, 18, 221-224.	2.3	1
1015	VALUE OF COMPUTED TOMOGRAPHY FOR EVALUATING THE INJECTION SITE IN ENDOSONOGRAPHY-GUIDED CELIAC PLEXUS NEUROLYSIS. <i>Digestive Endoscopy</i> , 2006, 18, 206-211.	2.3	16
1016	A proposal of the modified liver damage classification for hepatocellular carcinoma. <i>Hepatology Research</i> , 2006, 34, 124-129.	3.4	6
1017	Case of adult genotype C HBV carrier after acute hepatitis B, losing HBsAg and acquiring HBsAb after IFN and lamivudine treatment. <i>Hepatology Research</i> , 2006, 36, 149-152.	3.4	0
1018	Regulatory failure of serum prohepcidin levels in patients with hepatitis C. <i>Hepatology Research</i> , 2006, 36, 288-293.	3.4	57
1019	Consensus on extra-hepatic portal vein obstruction. <i>Liver International</i> , 2006, 26, 512-519.	3.9	224
1020	Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial. <i>Journal of Gastroenterology</i> , 2006, 41, 70-76.	5.1	26
1021	What is the best staging system for hepatocellular carcinoma?. <i>Journal of Gastroenterology</i> , 2006, 41, 290-291.	5.1	1
1022	Early Detection and Characterization of Hepatocellular Carcinoma: Value of Imaging Multistep Human Hepatocarcinogenesis. <i>Intervirolgy</i> , 2006, 49, 64-69.	2.8	14
1023	Clinical Significance of the Genotype and Core Promoter/Pre-Core Mutations in Hepatitis B Virus Carriers. <i>Intervirolgy</i> , 2006, 49, 200-206.	2.8	9
1024	Hepatocellular carcinoma metastasizing to the skull base involving multiple cranial nerves. <i>World Journal of Gastroenterology</i> , 2006, 12, 6727.	3.3	24
1025	Studies on the Variation in Clinical Laboratory Data and Safety Evaluation of Pharmaceuticals. <i>Yakugaku Zasshi</i> , 2005, 125, 997-1004.	0.2	1
1026	Clinical comparison of branched-chain amino acid (-Leucine, -Isoleucine, -Valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV&EN study). <i>Hepatology Research</i> , 2005, 31, 232-240.	3.4	47

#	ARTICLE	IF	CITATIONS
1027	Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. <i>Hepatology Research</i> , 2005, 32, 173-184.	3.4	180
1028	Multiple hypervascular liver nodules in a heavy drinker of alcohol. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 795-799.	2.8	10
1029	Staging for hepatocellular carcinoma: Treatment strategy matters. <i>Hepatology</i> , 2005, 41, 678-678.	7.3	8
1030	Reply:. <i>Hepatology</i> , 2005, 41, 678-679.	7.3	3
1031	Vascularity of gastric carcinoma: evaluation using color Doppler ultrasonography. <i>Journal of Medical Ultrasonics (2001)</i> , 2005, 32, 23-28.	1.3	0
1032	Multiple metastases from a meningeal hemangiopericytoma associated with severe hypoglycemia. <i>Journal of Medical Ultrasonics (2001)</i> , 2005, 32, 187-190.	1.3	4
1033	Imaging findings of biliary hamartomas (von Meyenburg complexes). <i>Journal of Medical Ultrasonics (2001)</i> , 2005, 32, 205-212.	1.3	5
1034	Hepatic angiomyolipoma: identification of an efferent vessel as a hepatic vein by contrast-enhanced harmonic sonography. <i>Journal of Medical Ultrasonics (2001)</i> , 2005, 32, 191-196.	1.3	3
1035	Hemodynamic and morphologic changes of peripheral hepatic vasculature in chronic liver disease: a preliminary study by contrast-enhanced coded phase-inversion harmonic sonography. <i>Journal of Medical Ultrasonics (2001)</i> , 2005, 32, 197-204.	1.3	1
1036	Estimation of the malignant potential of gastrointestinal stromal tumors: the value of contrast-enhanced coded phase-inversion harmonics US. <i>Journal of Gastroenterology</i> , 2005, 40, 247-255.	5.1	33
1037	Differential diagnosis of nodular lesions in cirrhotic liver by post-vascular phase contrast-enhanced US with Levovist: comparison with superparamagnetic iron oxide magnetic resonance images. <i>Journal of Gastroenterology</i> , 2005, 40, 1139-1147.	5.1	32
1038	Imaging findings of biliary hamartomas. <i>World Journal of Gastroenterology</i> , 2005, 11, 6354.	3.3	107
1039	Ischemia of rat stomach mobilizes ECL cell histamine. <i>American Journal of Physiology - Renal Physiology</i> , 2005, 288, G1084-G1090.	3.4	21
1040	Hepatic angiomyolipoma: identification of an efferent vessel to be hepatic vein by contrast-enhanced harmonic ultrasound. <i>British Journal of Radiology</i> , 2005, 78, 956-960.	2.2	23
1041	Low-Dose, Long-Term, Intermittent Interferon-alpha-2b Therapy after Radical Treatment by Radiofrequency Ablation Delays Clinical Recurrence in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma. <i>Intervirolgy</i> , 2005, 48, 64-70.	2.8	55
1042	Primary Sclerosing Cholangitis and Hepatitis C Virus Infection. <i>Intervirolgy</i> , 2005, 48, 268-272.	2.8	7
1043	Contrast-Enhanced Harmonic EUS: A Method to Visualize Microcirculation in Digestive Organs. <i>Gastrointestinal Endoscopy</i> , 2005, 61, AB288.	1.0	1
1044	Early Detection and Curative Treatment of Early-Stage Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, S144-S148.	4.4	38

#	ARTICLE	IF	CITATIONS
1045	Hemodynamic and morphologic changes of peripheral hepatic vasculature in cirrhotic liver disease: A preliminary study using contrast-enhanced coded phase inversion harmonic ultrasonography. World Journal of Gastroenterology, 2005, 11, 6348.	3.3	10
1046	Staging system for hepatocellular carcinoma. Acta Hepatologica Japonica, 2005, 46, 53-63.	0.1	1
1047	Forefront of radiofrequency ablation treatment of hepatic cancer. 1. Treatment indication (positioning of the treatment).. Acta Hepatologica Japonica, 2005, 46, 160-164.	0.1	0
1048	Well-differentiated HCC manifesting hyperattenuation on CT during arterial portography. Hepato-Gastroenterology, 2005, 52, 1559-62.	0.5	3
1049	Characterization of Hepatic Tumors:Value of Contrast-Enhanced Coded Phase-Inversion Harmonic Angio. American Journal of Roentgenology, 2004, 182, 1019-1026.	2.2	91
1050	Treatment of Hepatocellular Carcinoma with Percutaneous Radiofrequency Ablation:Usefulness of Contrast Harmonic Sonography for Lesions Poorly Defined with B-Mode Sonography. American Journal of Roentgenology, 2004, 183, 153-156.	2.2	81
1051	Percutaneous Radiofrequency Ablation Guided by Contrast-Enhanced Harmonic Sonography with Artificial Pleural Effusion for Hepatocellular Carcinoma in the Hepatic Dome. American Journal of Roentgenology, 2004, 182, 1224-1226.	2.2	61
1052	Dynamic imaging of pancreatic diseases by contrast enhanced coded phase inversion harmonic ultrasonography. Gut, 2004, 53, 854-859.	12.1	219
1053	Afferent and Efferent Vessels of Premalignant and Overt Hepatocellular Carcinoma: Observation by Color Doppler Imaging. Intervirology, 2004, 47, 144-153.	2.8	16
1054	Differentiation of Hepatic Tumors by Color Doppler Imaging: Role of the Maximum Velocity and the Pulsatility Index of the Intratumoral Blood Flow Signal. Intervirology, 2004, 47, 154-161.	2.8	13
1055	Detection of Intratumoral Vascularity in Small Hepatocellular Carcinoma by Coded Phase Inversion Harmonics. Intervirology, 2004, 47, 169-178.	2.8	13
1056	Hepatocellular Carcinoma with Nodule-in-Nodule Appearance: Demonstration by Contrast-Enhanced Coded Phase Inversion Harmonic Imaging. Intervirology, 2004, 47, 184-190.	2.8	13
1057	Atypical Large Well-Differentiated Hepatocellular Carcinoma with Benign Nature: A New Clinical Entity. Intervirology, 2004, 47, 227-237.	2.8	23
1058	Hypervascular Liver Nodules in Heavy Drinkers of Alcohol. Alcoholism: Clinical and Experimental Research, 2004, 28, 174S.	2.4	10
1059	Local ablation therapy for hepatocellular carcinoma: current status and future perspectives. Journal of Gastroenterology, 2004, 39, 205-214.	5.1	92
1060	Comparison of argon plasma coagulation and paravariceal injection sclerotherapy with 1% polidocanol in mucosa-fibrosing therapy for esophageal varices. Journal of Gastroenterology, 2004, 39, 397-399.	5.1	8
1061	Multiple tuberculous abscesses of the liver and the brain in a patient with acute leukemia. Journal of Gastroenterology, 2004, 39, 497-499.	5.1	7
1062	Hepatocellular carcinoma that ruptured during radiofrequency ablation therapy. Journal of Gastroenterology, 2004, 39, 1015-1016.	5.1	5

#	ARTICLE	IF	CITATIONS
1063	Hepatocellular carcinoma and NASH. Journal of Gastroenterology, 2004, 39, 409-411.	5.1	11
1064	Mucin phenotypic expression and background mucosa of esophagogastric junctional adenocarcinoma. Gastric Cancer, 2004, 7, 97-103.	5.3	11
1065	Diagnosis of acute cholecystitis in patients with liver cirrhosis: waveform analysis of the cystic artery by color Doppler imaging. Journal of Medical Ultrasonics (2001), 2004, 31, 21-28.	1.3	3
1066	Atypical focal spared area in fatty liver: evaluation by color Doppler ultrasonography. Journal of Medical Ultrasonics (2001), 2004, 31, 131-4.	1.3	0
1067	Validation of a new prognostic staging system for hepatocellular carcinoma: The JIS score compared with the CLIP score. Hepatology, 2004, 40, 1396-1405.	7.3	342
1068	Anisakis in a biopsy specimen from the edge of a gastric ulcer: report of a case. Gastrointestinal Endoscopy, 2004, 60, 854-856.	1.0	4
1069	Hypervascular Liver Nodules in Heavy Drinkers of Alcohol. Alcoholism: Clinical and Experimental Research, 2004, 28, 174S-180S.	2.4	4
1070	Detection of tumor vascularity in hepatocellular carcinoma with contrast-enhanced Dynamic Flow imaging: Comparison with contrast-enhanced power Doppler imaging. Journal of Medical Ultrasonics (2001), 2003, 30, 141-151.	1.3	9
1071	Contrast-enhanced agent detection imaging: Early experience in hepatocellular carcinoma. Journal of Medical Ultrasonics (2001), 2003, 30, 77-84.	1.3	8
1072	Value of new contrast harmonic technique for detecting tumor vascularity in hepatocellular carcinoma: Preliminary results. Journal of Medical Ultrasonics (2001), 2003, 30, 85-92.	1.3	7
1073	Assessment of image quality of contrast-enhanced power doppler imaging in hepatocellular carcinoma with the personal ultrasound imager: Comparison with the conventional machine. Journal of Medical Ultrasonics (2001), 2003, 30, 31-38.	1.3	4
1074	Scintigraphic study of regenerative nodules due to fulminant hepatic failure. Journal of Gastroenterology, 2003, 38, 695-699.	5.1	4
1075	Risk of HCV transmission after needlestick injury, and the efficacy of short-duration interferon administration to prevent HCV transmission to medical personnel. Journal of Gastroenterology, 2003, 38, 877-879.	5.1	30
1076	Percutaneous ultrasound-guided radiofrequency ablation with artificial pleural effusion for hepatocellular carcinoma in the hepatic dome. Journal of Gastroenterology, 2003, 38, 1066-1070.	5.1	65
1077	Transient portal vein thrombosis caused by radiofrequency ablation for hepatocellular carcinoma. Journal of Gastroenterology, 2003, 38, 101-103.	5.1	18
1078	Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). Journal of Gastroenterology, 2003, 38, 207-215.	5.1	644
1079	Hepatic nodular lesions caused by abnormal hepatic circulation: etiological and clinical aspects. Journal of Gastroenterology, 2003, 38, 308-310.	5.1	8
1080	Stage IV hepatocellular carcinoma with portal venous tumor thrombus: complete response after combined therapy of repeated arterial chemoembolization and radiofrequency ablation. Journal of Gastroenterology, 2003, 38, 406-409.	5.1	5

#	ARTICLE	IF	CITATIONS
1081	Spontaneous regurgitation of portal blood flow normalized by meal intake in a patient with alcoholic liver cirrhosis. Hepatology Research, 2003, 25, 143-148.	3.4	0
1082	Hepatocellular carcinoma mimicking cavernous hemangioma on angiography and contrast enhanced harmonic ultrasonography. A case report. Hepatology Research, 2003, 25, 202-212.	3.4	8
1083	Hepatocellular carcinoma associated with secondary haemochromatosis in non-cirrhotic liver: a case report. Hepatology Research, 2003, 26, 254-258.	3.4	15
1084	Hepatobiliary and pancreatic: Arteriportal fistula causing portal hypertension. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 873-873.	2.8	3
1085	Hepatobiliary and pancreatic: Inflammatory pseudotumor of the liver. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 994-994.	2.8	0
1086	Hepatobiliary and pancreatic: Fatty liver, spared areas and aberrant gastric venous drainage. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 1423-1423.	2.8	0
1087	Radiofrequency ablation therapy under contrast-enhanced harmonic imaging guidance for recurrence after local ablation therapy for hepatocellular carcinoma: A randomized controlled study. Gastroenterology, 2003, 124, A773.	1.3	0
1088	Changes of lens culinaris agglutinin-reactive alpha-fetoprotein (AFP-L3 fraction) after complete radiofrequency ablation for hepatocellular carcinoma. Gastroenterology, 2003, 124, A699.	1.3	0
1089	Validation and limitation of CLIP scoring system in 722 Japanese patients with hepatocellular carcinoma and a proposal of better prognostic staging system. Japan integrated staging score (JIS) Tj ETQq1 1 0.7843 14 rgB5/Overlo	1.3	0
1090	Radiofrequency ablation therapy for hepatocellular carcinoma located at subphrenic region: Value of artificial pleural effusion combined with contrast-Harmonic imaging. Gastroenterology, 2003, 124, A773.	1.3	0
1091	Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma:Usefulness of Coded Phase-Inversion Harmonic Sonography. American Journal of Roentgenology, 2003, 180, 703-708.	2.2	68
1092	Radiofrequency Ablation of Hepatocellular Carcinoma:Therapeutic Response Using Contrast-Enhanced Coded Phase-Inversion Harmonic Sonography. American Journal of Roentgenology, 2003, 181, 57-63.	2.2	101
1093	Contrast Harmonic Imaging in the Diagnosis and Treatment of Hepatic Tumors. , 2003, , .		27
1094	Harmonic Power Doppler and Other New Techniques on ALOKA ProSound Series. , 2003, , 31-68.		1
1095	Characterization of focal hepatic lesions with contrast-enhanced C-cube gray scale ultrasonography. World Journal of Gastroenterology, 2003, 9, 1667.	3.3	13
1096	Agent Detection Imaging (ADI) (Acuson Sequoia 512). , 2003, , 128-144.		0
1097	Contrast Imaging (Toshiba PowerVision 8000 and Aplio). , 2003, , 69-120.		0
1098	Intranodular Hemodynamic Transition Associated with Dedifferentiation of Hepatocellular Carcinoma. , 2003, , 12-13.		0

#	ARTICLE	IF	CITATIONS
1099	Natural history of untreated hepatocellular carcinoma: A retrospective multicenter study of 195 patients. <i>Acta Hepatologica Japonica</i> , 2003, 44, 546-551.	0.1	3
1100	Application of Contrast-Enhanced Harmonic Imaging in Biliary and Pancreatic Tumors. , 2003, , 248-250.		0
1101	Coded Harmonic Angio (GE LOGIQ 700 EXPERT Series). , 2003, , 145-179.		0
1102	Vascularity and Hemodynamics of Liver Tumors as Seen with Intraarterial Contrast-Enhanced Ultrasonography. , 2003, , 4-11.		0
1103	Update and Direction of Ultrasonic Contrast Agents. , 2003, , 251-253.		0
1104	Hepatobiliary and pancreatic: Hyperplastic nodules in cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 599-599.	2.8	0
1105	Somatic mutation and SNP in the promoter of dbpA and human hepatocarcinogenesis. <i>International Journal of Oncology</i> , 2002, 21, 847.	3.3	13
1106	Imaging Blood Flow Characteristics of Hepatocellular Carcinoma. <i>Oncology</i> , 2002, 62, 48-56.	1.9	45
1107	Endoscopic band ligation for control of nonvariceal upper GI hemorrhage: Comparison with bipolar electrocoagulation. <i>Gastrointestinal Endoscopy</i> , 2002, 55, 214-218.	1.0	85
1108	Contrast advanced dynamic flow imaging and contrast pulse subtraction imaging: Preliminary results in hepatic tumors. <i>Journal of Medical Ultrasonics (2001)</i> , 2002, 29, 195-204.	1.3	9
1109	The efferent blood flow of early hepatocellular carcinoma and borderline lesions: Demonstration by color Doppler imaging. <i>Journal of Medical Ultrasonics (2001)</i> , 2002, 29, 205-209.	1.3	5
1110	Evaluation of image quality of personal ultrasound imager: Comparison with the conventional machine. <i>Journal of Medical Ultrasonics (2001)</i> , 2002, 29, 41-46.	1.3	1
1111	Proximal bifurcation of hepatic artery: Novel findings on hepatic arteries demonstrated by ultrasound Doppler imaging, B-flow, and US angiography. <i>Journal of Medical Ultrasonics (2001)</i> , 2002, 29, 11-17.	1.3	1
1112	Development of multicentric hepatocellular carcinoma after completion of interferon therapy. <i>Journal of Gastroenterology</i> , 2002, 37, 663-668.	5.1	13
1113	CEA producing primary hepatic carcinoid. <i>Hepatology Research</i> , 2002, 22, 313-321.	3.4	14
1114	Intrahepatic huge hematoma due to rupture of small hepatocellular adenoma: a case report. <i>Hepatology Research</i> , 2002, 23, 145-151.	3.4	12
1115	Eosinophilic pseudotumor of the liver due to <i>Ascaris suum</i> infection. <i>Hepatology Research</i> , 2002, 23, 306-314.	3.4	11
1116	Application of contrast-enhanced ultrasonography to the local treatment of hepatocellular carcinoma. <i>Journal of Microwave Surgery</i> , 2002, 20, 17-25.	0.3	0

#	ARTICLE	IF	CITATIONS
1117	Hepatic peribiliary cysts: clinically harmless disease with potential risk due to gradual increase in size and number. <i>Journal of Gastroenterology</i> , 2001, 36, 286-288.	5.1	21
1118	Hepatocellular adenoma in type Ia glycogen storage disease. <i>Journal of Gastroenterology</i> , 2001, 36, 65-66.	5.1	23
1119	Contrast harmonic ultrasound is a breakthrough technology in the diagnosis and treatment of hepatocellular carcinoma. <i>Journal of Medical Ultrasonics</i> (2001), 2001, 28, 79-81.	1.3	21
1120	Agenesis of the left lobe of the liver: Radiologic findings. <i>Journal of Medical Ultrasonics</i> (2001), 2001, 28, 181-183.	1.3	1
1121	Vascularity of advanced gastric carcinoma: Evaluation by using power Doppler imaging. <i>Journal of Gastroenterology and Hepatology</i> (Australia), 2001, 16, 149-153.	2.8	5
1122	Cerebral vascular resistance in hepatic insufficiency. <i>Journal of Gastroenterology and Hepatology</i> (Australia), 2001, 16, 845-847.	2.8	5
1123	Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of <i>Lens culinaris</i> agglutinin- α -fetoprotein ¹ . <i>Journal of Gastroenterology and Hepatology</i> (Australia), 2001, 16, 1378-1383.	2.8	127
1124	A case of localized primary sclerosing cholangitis mimicking intrahepatic bile duct cancer. <i>Hepatology Research</i> , 2001, 20, 259-264.	3.4	3
1125	Detection of tumor parenchymal blood flow in hepatic tumors: value of second harmonic imaging with a galactose-based contrast agent. <i>Hepatology Research</i> , 2001, 21, 242-251.	3.4	21
1126	Sonographic diagnosis of pancreatic islet cell tumor: Value of intermittent harmonic imaging. <i>Journal of Clinical Ultrasound</i> , 2001, 29, 411-416.	0.8	30
1127	Intrahepatic Spontaneous Retrograde Portal Flow in Patients with Cirrhosis of the Liver. <i>American Journal of Roentgenology</i> , 2001, 177, 1109-1112.	2.2	12
1128	Hepatocellular Carcinoma: Depiction of Tumor Parenchymal Flow with Intermittent Harmonic Power Doppler US during the Early Arterial Phase in Dual-Display Mode. <i>Radiology</i> , 2001, 220, 349-356.	7.3	83
1129	Evaluation of Posttreatment Response of Hepatocellular Carcinoma with Contrast-enhanced Coded Phase-Inversion Harmonic US: Comparison with Dynamic CT. <i>Radiology</i> , 2001, 221, 721-730.	7.3	130
1130	Contrast-Enhanced Subtraction Harmonic Sonography for Evaluating Treatment Response in Patients with Hepatocellular Carcinoma. <i>American Journal of Roentgenology</i> , 2001, 176, 661-666.	2.2	84
1131	Riedel's Lobe of the Liver and Its Clinical Implication. <i>Internal Medicine</i> , 2000, 39, 87-88.	0.7	25
1132	TTV Positivity and Transfusion History in Non-B, Non-C Hepatocellular Carcinoma Compared with HBV- and HCV-Positive Cases. <i>Intervirology</i> , 2000, 43, 13-15.	2.8	12
1133	Repeated Hepatic Arterial Chemoembolization Therapy for Management of A Patient With Metastatic Carcinoid Tumors of The Liver. <i>American Journal of Gastroenterology</i> , 2000, 95, 1842-1843.	0.4	3
1134	Letters to the Editor. <i>Journal of Hepatology</i> , 2000, 33, 857-858.	3.7	12

#	ARTICLE	IF	CITATIONS
1135	Repeated hepatic arterial chemoembolization therapy for management of a patient with metastatic carcinoid tumors of the liver. <i>American Journal of Gastroenterology</i> , 2000, 95, 1842-1843.	0.4	0
1136	Imaging Diagnosis of Hepatocellular Carcinoma and Premalignant/Borderline Lesions. <i>Seminars in Liver Disease</i> , 1999, 19, 297-309.	3.6	110
1137	Massive rectal bleeding due to ileal tuberculosis. <i>Journal of Gastroenterology</i> , 1999, 34, 525-529.	5.1	14
1138	Inflammatory pseudotumor of the liver in a patient with chronic hepatitis C: Difficulty in differentiating it from hepatocellular carcinoma. <i>Pathology International</i> , 1999, 49, 726-730.	1.3	22
1139	Cronkhite-Canada syndrome associated with triple gastric cancers: a case report. <i>Gastrointestinal Endoscopy</i> , 1999, 50, 688-691.	1.0	31
1140	The Draining Vessel of Advanced Hepatocellular Carcinoma: Assessment of Color Doppler Findings in Comparison with Histopathological Findings.. <i>Acta Hepatologica Japonica</i> , 1999, 40, 243-252.	0.1	3
1141	A case of well-differentiated minute hepatocellular carcinoma with extrahepatic metastasis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998, 13, 892-896.	2.8	5
1142	Hepatocellular Carcinomas Infected with the Novel TT DNA Virus Lack Viral Integration. <i>Biochemical and Biophysical Research Communications</i> , 1998, 251, 339-343.	2.1	44
1143	Compartmental analysis of asialoglycoprotein receptor scintigraphy for quantitative measurement of liver function: A multicentre study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 130-137.	2.1	49
1144	[27] Synthesis and radiolabeling of galactosyl human serum albumin. <i>Methods in Enzymology</i> , 1994, 247, 383-394.	1.0	9
1145	[29] Radiopharmaceutical preparation of technetium-99m-labeled galactosyl neoglycoalbumin. <i>Methods in Enzymology</i> , 1994, 247, 402-409.	1.0	1
1146	[26] In Vivo quantification of asialoglycoprotein receptor. <i>Methods in Enzymology</i> , 1994, 247, 373-382.	1.0	3
1147	Hepatic Receptor Imaging Using Radiolabeled Asialoglycoprotein Analogs. , 1994, , 373-402.		3
1148	Quantitative assessment of hepatocellular function throughin vivo radioreceptor imaging with technetium 99m galactosyl human serum albumin. <i>Hepatology</i> , 1993, 17, 814-819.	7.3	72
1149	Measurement of functioning hepatocyte mass via [99mTc]galactosyl-neoglycoalbumin. <i>Digestive Diseases and Sciences</i> , 1993, 38, 2183-2188.	2.3	4
1150	Hepatic angiomyolipoma pre-operatively diagnosed by imaging. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1993, 8, 483-488.	2.8	26
1151	In Vivo Functional Imaging Using Receptor-Binding Radiopharmaceuticals. <i>Investigative Radiology</i> , 1993, 28, 64-70.	6.2	19
1152	Endoscopic retrograde extraction of common bile duct stones with drip infusion of isosorbide dinitrate. <i>Gastrointestinal Endoscopy</i> , 1992, 38, 178-180.	1.0	28

#	ARTICLE	IF	CITATIONS
1153	Hemodynamic characteristics of early stage hepatocellular carcinoma: In vivo evaluation with vascular imagings.. Acta Hepatologica Japonica, 1992, 33, 283-291.	0.1	10
1154	Growth speed of hepatocellular carcinoma. Relationship with arterial vascularity evaluated by US angiography.. Acta Hepatologica Japonica, 1992, 33, 758-765.	0.1	7
1155	Hepatic uptake of [99mTc]galactosyl-neoglycoalbumin is sensitive to receptor quantity. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1991, 18, 663-666.	0.3	4
1156	Functional hepatic imaging with receptor-binding radiopharmaceutical: Clinical potential as a measure of functioning hepatocyte mass. Gastroenterologia Japonica, 1991, 26, 734-741.	0.3	48
1157	In Vivo Measurement of Hepatic Binding Protein Using Galactosyl-Neoglycoalbumin: Clinical Application as a New Liver Function Test.. Trends in Glycoscience and Glycotechnology, 1991, 3, 193-199.	0.1	1
1158	Avid Accumulation of Ga-67 Citrate in Adenocarcinoma of Pancreas. Clinical Nuclear Medicine, 1989, 14, 843-845.	1.3	4
1159	Evaluation of asialoglycoprotein receptor-binding, synthetic radiolabeled glycoprotein in estimating hepatic functional reserve.. Acta Hepatologica Japonica, 1987, 28, 1277-1286.	0.1	3
1160	Accumulation of Tc-99m Methylene Diphosphonate in Calcified Metastatic Lesions of the Liver from Colonic Carcinoma. Clinical Nuclear Medicine, 1985, 10, 9-12.	1.3	9
1161	Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Non-inflamed Subclass. Liver Cancer, 0, , .	7.7	6
1162	Pancreatic neuroendocrine carcinoma with unique morphological features mimicking intraductal papillary mucinous carcinoma: A case report. Frontiers in Medicine, 0, 9, .	2.6	0